International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 71

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–109) and Recommended (1–70) International Nonproprietary Names can be found in *Cumulative List No. 15, 2013* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 71

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–109) et recommandées (1–70) dans la *Liste récapitulative No. 15, 2013* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 71

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–109) y Recomendadas (1–70) se encuentran reunidas en *Cumulative List No. 15, 2013* (disponible sólo en CD-ROM).

Latin, English, French, Spanish: *Recommended INN*	*Chemical name or description; Molecular formula; Graphic formula*
DCI Recommandée	*Nom chimique ou description; Formule brute; Formule développée*
DCI Recomendada	*Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada*

abaloparatidum

abaloparatide

synthetic human parathyroid hormone (37-70) analogue: $C^{2,29}$-methyl[22-L-glutamic acid(F>E),23-L-leucine(F>L),25-L-glutamic acid(H>E),26-L-lysine(H>K),28-L-leucine(I>L),30-L-lysine(E>K), 31-L-leucine(I>L)]human parathyroid hormone-related protein-(1-34)-proteinamide

abaloparatide

analogue de l'hormone parathyroïdienne humaine (37-70) synthétique: $C^{2,29}$-méthyl[22-L-acide glutamique(F>E),23-L-leucine(F>L), 25-L-acide glutamique(H>E),26-L-lysine(H>K),28-L-leucine(I>L), 30-L-lysine(E>K),31-L-leucine(I>L)]protéine apparentée à l'hormone parathyroïdienne humaine-(1-34)-protéinamide

abaloparatida

análogo sintético de la hormona paratiroidea humana (37-70): $C^{2,29}$-metil[22-L-ácido glutámico(F>E),23-L-leucina(F>L),25-L-ácido glutámico(H>E),26-L-lisina(H>K),28-L-leucina(I>L), 30-L-lisina(E>K),31-L-leucina(I>L)]proteína relacionada con la hormona paratiroidea humana-(1-34)-proteinamida

$C_{174}H_{300}N_{56}O_{49}$

Sequence / Séquence / Secuencia

AVSEHQLLHD KGKSIQDLRR RELLEKLLXK LHTA 34

Modified residues / Résidus modifiés / Restos modificados



abecomotidum

abecomotide

human insulin-like growth factor 2 mRNA-binding protein 3 (IMP-3, hKOC)-(508-513)-peptide (part of the KH4 domain): L-lysyl-L-threonyl-L-valyl-L-asparaginyl-L-α-glutamyl-L-leucyl-L-glutaminyl-L-asparaginyl-L-leucine

abécomotide

protéine 3, se liant à l'ARN messager, du facteur 2 de croissance humain analogue de l'insuline (IMP-3, hKOC)-(508-513)-peptide (partie du domaine KH4): L-lysyl-L-thréonyl-L-valyl-L-asparaginyl-L-α-glutamyl-L-leucyl-L-glutaminyl-L-asparaginyl-L-leucine

abecomotida

proteína 3, que se une al ARN mensajero del factor 2 de crecimiento humano análogo de la insulina (IMP-3, hKOC)-(508-513)-péptido (parte del dominio KH4) : L-lisil-L-treonil-L-valil-L-asparaginil-L-α-glutamil-L-leucil-L-glutaminil-L-asparaginil-L-leucina

$C_{45}H_{79}N_{13}O_{16}$

Sequence / Séquence / Secuencia

KTVNELQNL 9

abituzumabum #

abituzumab

immunoglobulin G2-kappa, anti-[*Homo sapiens* ITGAV (integrin alphaV, CD51)], humanized monoclonal antibody;
gamma2 heavy chain (1-447) with IGHG1 hinge region [humanized VH (*Homo sapiens* IGHV1-46*01 (77.30%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) -*Homo sapiens* IGHG (IGHG2*03 CH1 (119-216), IGHG1 hinge C5>S (221) (217-231), IGHG2*03 CH2 F84.3>A (296), N84.4>Q (297) (232-340), CH3 (341-445), CHS (446-447)) (119-447)], (132-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-33*01 (86.30%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimer (227-227":230-230")-bisdisulfide

abituzumab

immunoglobuline G2-kappa, anti-[*Homo sapiens* ITGAV (intégrine alphaV, CD51)], anticorps monoclonal humanisé;
chaîne lourde gamma2 (1-447) avec une région charnière IGHG1 [VH humanisé (*Homo sapiens* IGHV1-46*01 (77.30%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) -*Homo sapiens* IGHG (IGHG2*03 CH1 (119-216), IGHG1 charnière C5>S (221) (217-231), IGHG2*03 CH2 F84.3>A (296), N84.4>Q (297) (232-340), CH3 (341-445), CHS (446-447)) (119-447)], (132-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-33*01 (86.30%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimère (227-227":230-230")-bisdisulfure

abituzumab

inmunoglobulina G2-kappa, anti-[ITGAV (integrina alfaV, CD51) de *Homo sapiens*], anticuerpo monoclonal humanizado; cadena pesada gamma2 (1-447) con una región bisagra GHG1 [VH humanizada (*Homo sapiens* IGHV1-46*01 (77.30%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) -*Homo sapiens* IGHG (IGHG2*03 CH1 (119-216), IGHG1 bisagra C5>S (221) (217-231), IGHG2*03 CH2 F84.3>A (296), N84.4>Q (297) (232-340), CH3 (341-445), CHS (446-447)) (119-447)], (132-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizada (*Homo sapiens* IGKV1-33*01 (86.30%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dímero (227-227":230-230")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQQSGGE LAKPGASVKV SCKASGYTFS SFWMHWVRQA PGQGLEWIGY 50
INPRSGYTEY NEIFRDKATM TTDTSTSTAY MELSSLRSED TAVYYCASFL 100
GRGAMDYWGQ GTTVTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSNFGTQTYT 200
CNVDHKPSNT KVDKTVEPKS SDKTHTCPPC PAPPVAGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVQFNWYVD GVEVHNAKTK PREEQAQSTF 300
RVVSVLTVVH QDWLNGKEYK CKVSNKGLPA PIEKTISKTK GQPREPQVYT 350
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPMLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK    447
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRASQDIS NYLAWYQQKP GKAPKLLIYY  50
TSKIHSGVPS RFSGSGSGTD YTFTISSLQP EDIATYYCQQ GNTFPYTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	145-201	261-321	367-425
	22"-96"	145"-201"	261"-321"	367"-425"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (CH1 10-CL 126)	132-214'	132"-214'"		
Inter-H-H (h 11, h 14)	227-227"	230-230"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
None (owing to amino acid change: H CH2 N84.4>Q (297)), aucun (dû au changement d'acide aminé), ninguno (a causa del cambio de ácido amino)

acalisibum

acalisib — 6-fluoro-3-phenyl-2-[(1*S*)-1-(7*H*-purin-6-ylamino)ethyl]quinazolin-4(3*H*)-one

acalisib — 6-fluoro-3-phényl-2-[(1*S*)-1-(7*H*-purin-6-ylamino)éthyl]quinazolin-4(3*H*)-one

acalisib — 6-fluoro-3-fenil-2-[(1*S*)-1-(7*H*-purin-6-ilamino)etil]quinazolin-4(3*H*)-ona

$C_{21}H_{16}FN_7O$



aftobetinum

aftobetin — 2-[2-(2-methoxyethoxy)ethoxy]ethyl (2*E*)-2-cyano-3-[6-(piperidin-1-yl)naphthalen-2-yl]prop-2-enoate

aftobétine — (2*E*)-2-cyano-3-[6-(pipéridin-1-yl)naphtalén-2-yl]prop-2-énoate de 2-[2-(2-méthoxyéthoxy)éthoxy]éthyle

aftobetina — (2*E*)-2-ciano-3-[6-(piperidin-1-il)naftalen-2-il]prop-2-enoato de 2-[2-(2-metoxietoxi)etoxi]etilo

$C_{26}H_{32}N_2O_5$ 1208971-05-4



alicdamotidum

alicdamotide — human kinetochore protein Nuf2 (cell division cycle-associated protein 1)-(55-64)-peptide

alicdamotide — protéine cinétochore Nuf2 humaine (protéine 1 associée au cycle de la division cellulaire)-(55-64)-peptide

alicdamotida — proteína humana de cinetocoro Nuf2 (proteína 1 asociada al ciclo de división celular)-(55-64)-péptido

$C_{54}H_{80}N_{14}O_{13}$

Sequence / Séquence / Secuencia
VYGIRLEHF 9

anetumabum ravtansinum #

anetumab ravtansine

immunoglobulin G1-lambda2, anti-[*Homo sapiens* MSLN (mesothelin, pre-pro-megakaryocyte-potentiating factor, megakaryocyte potentiating factor, MPF, CAK1)], *Homo sapiens* monoclonal antibody conjugated to maytansinoid DM4; gamma1 heavy chain (1-450) [*Homo sapiens* VH (IGHV5-51*01 (94.90%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -IGHG1*01 (CH1 (121-218), hinge (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-216')-disulfide with lambda light chain (1'-217') [*Homo sapiens* V-LAMBDA (IGLV2-14*01 (95.60%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 A43>G (155) (112'-217')]; dimer (229-229'':232-232'')-bisdisulfide; conjugated, on an average of 3 lysyl, to maytansinoid DM4 [$N^{2'}$-deacetyl-$N^{2'}$-(4-mercapto-4-methyl-1-oxopentyl)-maytansine] via the reducible SPDB linker [*N*-succinimidyl 4-(2-pyridyldithio)butanoate]
For the *ravtansine* part, please refer to the document *"INN for pharmaceutical substances: Names for radicals, groups and others"**

anétumab ravtansine

immunoglobuline G1-lambda2, anti-[*Homo sapiens* MSLN (mésothéline, facteur de potentialisation du pré-pro-mégacaryocyte, facteur de potentialisation des mégacaryocytes, MPF, CAK1)], *Homo sapiens* anticorps monoclonal conjugué au maytansinoïde DM4; chaîne lourde gamma1 (1-450) [*Homo sapiens* VH (IGHV5-51*01 (94.90%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -IGHG1*01 (CH1 (121-218), charnière (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-216')-disulfure avec la chaîne légère lambda (1'-217') [*Homo sapiens* V-LAMBDA (IGLV2-14*01 (95.60%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 A43>G (155) (112'-217')]; dimère 229-229'':232-232'')-bisdisulfure; conjugué, sur 3 lysyl en moyenne, au maytansinoïde DM4 [$N^{2'}$-déacétyl-$N^{2'}$-(4-mercapto-4-méthyl-1-oxopentyl)-maytansine] via le linker SPDB réductible [4-(2-pyridyldithio)butanoate de *N*-succinimidyle]
Pour la partie *ravtansine*, veuillez-vous référer au document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

anetumab ravtansina

inmunoglobulina G1-lambda2, anti-[MSLN de *Homo sapiens* (mesotelina, factor de potenciación del pre-pro-megacariocito, factor de potenciación de megacariocitos, MPF, CAK1)], anticuerpo monoclonal de *Homo sapiens* conjugado con el maitansinoide DM4; cadena pesada gamma1 (1-450) [*Homo sapiens* VH (IGHV5-51*01 (94.90%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -IGHG1*01 (CH1 (121-218), bisagra (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-216')-disulfuro con la cadena ligera lambda (1'-217') [*Homo sapiens* V-LAMBDA (IGLV2-14*01 (95.60%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 A43>G (155) (112'-217')]; dimère 229-229'':232-232'')-bisdisulfuro; conjugado, en tres restos lisil por término medio, con el maitansinoide DM4 [$N^{2'}$-desacetil-$N^{2'}$-(4-mercapto-4-metil-1-oxopentil)-maitansina] mediante el conector SPDB reducible [4-(2-piridilditio)butanoato de *N*-succinimidilo]
La información sobre la *ravtansina*, la encontrarán en el documento *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

Heavy chain / Chaîne lourde / Cadena pesada

```
QVELVQSGAE VKKPGESLKI SCKGSGYSFT SYWIGWVRQA PGKGLEWMGI  50
IDPGDSRTRY SPSFQGQVTI SADKSISTAY LQWSSLKASD TAMYYCARGQ 100
LYGGTYMDGW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450
```

Light chain / Chaîne légère / Cadena ligera

```
DIALTQPASV SGSPGQSITI SCTGTSSDIG GYNSVSWYQQ HPGKAPKLMI  50
YGVNNRPSGV SNRFSGSKSG NTASLTISGL QAEDEADYYC SSYDIESATP 100
VFGGGTKLTV LGQPKAAPSV TLFPPSSEEL QANKATLVCL ISDFYPGAVT 150
VAWKGDSSPV KAGVETTTPS KQSNNKYAAS SYLSLTPEQW KSHRSYSCQV 200
THEGSTVEKT VAPTECS                                     217
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	147-203	264-324	370-428
	22"-96"	147"-203"	264"-324"	370"-428"
Intra-L (C23-C104)	22'-90'	139'-198'		
	22'"-90'"	139'"-198'"		
Inter-H-L (h 5-CL 126)	223-216'	223"-216'"		
Inter-H-H (h 11, h 14)	229-229"	232-232"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
300, 300"

For the *ravtansine* part, please refer to the document "*INN for pharmaceutical substances: Names for radicals, groups and others*"*
Pour la partie *ravtansine,* veuillez vous référer au document "*INN for pharmaceutical substances: Names for radicals, groups and others*"*.
Para la fracción *ravtansina,* se pueden dirigir al documento "*INN for pharmaceutical substances: Names for radicals, groups and others*"*.

anifrolumabum #	
anifrolumab	immunoglobulin G1-kappa, anti-[*Homo sapiens* IFNAR1 (interferon alpha, beta and omega receptor 1, interferon alpha/beta receptor 1)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-447) [*Homo sapiens* VH (IGHV5-51*01 (93.90%) -(IGHD)-IGHJ2*01) [8.8.10] (1-117) -IGHG1*01 (CH1 (118-215), hinge (216-230), CH2 L1.3>F (234), L1.2>E (235), P116>S (331) (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (94.70%) -IGKJ5*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; dimer (226-226'':229-229'')-bisdisulfide
anifrolumab	immunoglobuline G1-kappa, anti-[*Homo sapiens* IFNAR1 (récepteur 1 de l'interféron alpha, bêta and oméga, récepteur de l'interféron alpha/bêta)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-447) [*Homo sapiens* VH (IGHV5-51*01 (93.90%) -(IGHD)-IGHJ2*01) [8.8.10] (1-117) -IGHG1*01 (CH1 (118-215), charnière (216-230), CH2 L1.3>F (234), L1.2>E (235), P116>S (331) (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V- KAPPA (IGKV3-20*01 (94.70%) -IGKJ5*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; dimère (226-226'':229-229'')-bisdisulfure
anifrolumab	inmunoglobulina G1-kappa, anti-[IFNAR1 de *Homo sapiens* (receptor 1 de interferón alfa, beta and omega, receptor de interferón alfa/beta)], anticuerpo monoclonal de *Homo sapiens* ; cadena pesada gamma1 (1-447) [*Homo sapiens* VH (IGHV5-51*01 (93.90%) -(IGHD)-IGHJ2*01) [8.8.10] (1-117) -IGHG1*01 (CH1 (118-215), bisagra (216-230), CH2 L1.3>F (234), L1.2>E (235), P116>S (331) (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V- KAPPA (IGKV3-20*01 (94.70%) -IGKJ5*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; dímero (226-226'':229-229'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVQSGAE VKKPGESLKI SCKGSGYIFT NYWIAWVRQM PGKGLESMGI  50
IYPGDSDIRY SPSFQGQVTI SADKSITTAY LQWSSLKASD TAMYYCARHD 100
IEGFDYWGRG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APEFEGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA SIEKTISKAK GQPREPQVYT 350
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK    447
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPGT LSLSPGERAT LSCRASQSVS SSFFAWYQQK PGQAPRLLIY  50
GASSRATGIP DRLSGSGSGT DFTLTITRLE PEDFAVYYCQ QYDSSAITFG 100
QGTRLEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC                                       215
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 144-200 261-321 367-425
22"-96" 144"-200" 261"-321" 367"-425"
Intra-L (C23-C104) 23'-89' 135'-195'
23'"-89'" 135'"-195'"
Inter-H-L (h 5-CL 126) 220-215' 220"-215'"
Inter-H-H (h 11, h 14) 226-226" 229-229"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
297, 297"

artefenomelum

artefenomel — 4-{2-{4-(*cis*-dispiro[adamantane-2,3'-[1,2,4]trioxolane-5',1"-cyclohexane]-4"-yl)phenoxy]ethyl}morpholine

artéfénomel — 4-{2-{4-(*cis*-dispiro[adamantane-2,3'-[1,2,4]trioxolane-5',1"-cyclohexane]-4"-yl)phénoxy]éthyl}morpholine

artefenomel — 4-{2-{4-(*cis*-diespiro[adamantano-2,3'-[1,2,4]trioxolano-5',1"-ciclohexano]-4"-il)fenoxi]etil}morfolina

$C_{28}H_{39}NO_5$



asapiprantum

asapiprant — 2-[2-(oxazol-2-yl)-5-(4-{4-[(propan-2-yl)oxy]benzenesulfonyl}piperazin-1-yl)phenoxy]acetic acid

asapiprant — acide 2-[2-(oxazol-2-yl)-5-(4-{4-[(propan-2-yl)oxy]benzènesulfonyl}pipérazin-1-yl)phénoxy]acétique

asapiprant — ácido 2-[2-(oxazol-2-il)-5-(4-{4-[(propan-2-il)oxi]bencenosulfonil}piperazin-1-il)fenoxi]acético

$C_{24}H_{27}N_3O_7S$



axelopranum

axelopran — 3-{(1*R*,3*r*,5*S*)-8-(2-{cyclohexylmethyl[(2*S*)-2,3-dihydroxypropanoyl]amino}ethyl)-8-azabicyclo[3.2.1]octan-3-yl}benzamide

axélopran — 3-[(1*R*,3*r*,5*S*)-8-(2-{(cyclohexylméthyl)[(2*S*)-2,3-dihydroxypropanoyl]amino}éthyl)-8-azabicyclo[3.2.1]octan-3-yl]benzamide

axeloprán — 3-{(1*R*,3*r*,5*S*)-8-(2-{ciclohexilmetil[(2*S*)-2,3-dihidroxipropanoil]amino}etil)-8-azabiciclo[3.2.1]octan-3-il}benzamida

$C_{26}H_{39}N_3O_4$



basimglurantum

basimglurant — 2-chloro-4-{2-[1-(4-fluorophenyl)-2,5-dimethyl-1*H*-imidazol-4-yl]ethynyl}pyridine

basimglurant — 2-chloro-4-{2-[1-(4-fluorophényl)-2,5-diméthyl-1*H*-imidazol-4-yl]éthynyl}pyridine

basimglurant — 2-cloro-4-{2-[1-(4-fluorofenil)-2,5-dimetil-1*H*-imidazol-4-il]etin-1-il}piridina

$C_{18}H_{13}ClFN_3$



binimetinibum

binimetinib — 5-[(4-bromo-2-fluorophenyl)amino]-4-fluoro-*N*-(2-hydroxyethoxy)-1-methyl-1*H*-benzimidazole-6-carboxamide

binimétinib — 5-[(4-bromo-2-fluorophényl)amino]-4-fluoro-*N*-(2-hydroxyéthoxy)-1-méthyl-1*H*-benzimidazole-6-carboxamide

binimetinib — 5-[(4-bromo-2-fluorofenil)amino]-4-fluoro-*N*-(2-hidroxietoxi)-1-metil-1*H*-benzoimidazol-6-carboxamida

$C_{17}H_{15}BrF_2N_4O_3$



ceralifimodum

ceralifimod — 1-({6-[(2-methoxy-4-propylphenyl)methoxy]-1-methyl-3,4-dihydronaphthalen-2-yl}methyl)azetidine-3-carboxylic acid

céralifimod — acide 1-({6-[(2-méthoxy-4-propylphényl)méthoxy]-1-méthyl-3,4-dihydronaphtalén-2-yl}méthyl)azétidine-3-carboxylique

ceralifimod — ácido 1-({1-metil-6-[(2-metoxi-4-propilfenil)metoxi]-3,4-dihidronaftalen-2-il}metil)azetidina-3-carboxílico

$C_{27}H_{33}NO_4$



ceritinibum

ceritinib — 5-chloro-*N*^{2}-{5-methyl-4-(piperidin-4-yl)-2-[(propan-2-yl)oxy]phenyl}-*N*^{4}-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine

céritinib — 5-chloro-*N*^{2}-{5-méthyl-4-(pipéridin-4-yl)-2-[(propan-2-yl)oxy]phényl}-*N*^{4}-[2-(propane-2-sulfonyl)phényl]pyrimidine-2,4-diamine

ceritinib — 5-cloro-*N*^{2}-{5-metil-4-(piperidin-4-il)-2-[(propan-2-il)oxi]fenil}-*N*^{4}-[2-(propano-2-sulfonil)fenil]pirimidina-2,4-diamina

$C_{28}H_{36}ClN_5O_3S$



codrituzumabum #

codrituzumab — immunoglobulin G1-kappa, anti-[*Homo sapiens* GPC3 (glypican 3)], humanized monoclonal antibody;
gamma1 heavy chain (1-445) [humanized VH (*Homo sapiens* IGHV1-46*01 (82.70%) -(IGHD)-IGHJ5*02) [8.8.8] (1-115) -*Homo sapiens* IGHG1*01 (CH1 (116-213, hinge (214-228), CH2 (229-338), CH3 (339-443), CHS (444-445)) (116-445)], (218-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV2-28*01 (86.00%) -IGKJ2*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dimer (224-224":227-227")-bisdisulfide

codrituzumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* GPC3 (glypicane 3)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-445) [VH humanisé (*Homo sapiens* (*Homo sapiens* IGHV1-46*01 (82.70%) -(IGHD)-IGHJ5*02) [8.8.8] (1-115) -*Homo sapiens* IGHG1*01 (CH1 (116-213, charnière (214-228), CH2 (229-338), CH3 (339-443), CHS (444-445)) (116-445)], (218-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV2-28*01 (86.00%) -IGKJ2*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dimère (224-224":227-227")-bisdisulfure

codrituzumab

inmunoglobulina G1-kappa, anti-[GPC3 (glipicano 3) de *Homo sapiens*], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-445) [VH humanizado (*Homo sapiens* (*Homo sapiens* IGHV1-46*01 (82.70%) -(IGHD)-IGHJ5*02) [8.8.8] (1-115) -*Homo sapiens* IGHG1*01 (CH1 (116-213, bisagra (214-228), CH2 (229-338), CH3 (339-443), CHS (444-445)) (116-445)], (218-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (*Homo sapiens* IGKV2-28*01 (86.00%) -IGKJ2*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')];dímero (224-224":227-227")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYTFT DYEMHWVRQA PGQGLEWMGA  50
LDPKTGDTAY SQKFKGRVTL TADKSTSTAY MELSSLTSED TAVYYCTRFY 100
SYTYWGQGTL VTVSSASTKG PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE 150
PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS LGTQTYICNV 200
NHKPSNTKVD KKVEPKSCDK THTCPPCPAP ELLGGPSVFL FPPKPKDTLM 250
ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV 300
VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLP 350
PSRDELTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 400
SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK      445
```

Light chain / Chaîne légère / Cadena ligera

```
DVVMTQSPLS LPVTPGEPAS ISCRSSQSLV HSNRNTYLHW YLQKPGQSPQ  50
LLIYKVSNRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCSQNTHVP 100
PTFGQGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	142-198	259-319	365-423
	22"-96"	142"-198"	259"-319"	365"-423"
Intra-L (C23-C104)	23'-93'	139'-199'		
	23'"-93'"	139'"-199'"		
Inter-H-L (h 5-CL 126)	218-219'	218"-219'"		
Inter-H-H (h 11, h 14)	224-224"	227-227"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
295, 295"

coltuximabum ravtansinum #

coltuximab ravtansine

immunoglobulin G1-kappa, anti-[*Homo sapiens* CD19 (B lymphocyte surface antigen B4, Leu-12)], chimeric monoclonal antibody conjugated to maytansinoid DM4;
gamma1 heavy chain (1-450) [*Mus musculus* VH (IGHV1-69*02 -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*01 (CH1 (121-218), hinge (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-211')-disulfide with kappa light chain (1'-211') [*Mus musculus* V-KAPPA (IGKV4-70*01 -IGKJ1*01) [5.3.7] (1'-104') -*Homo sapiens* IGKC*01 (105'-211')]; dimer (229-229'':232-232'')-bisdisulfide; conjugated, on an average of 3 to 4 lysyl, to maytansinoid DM4 [N^2-deacetyl-N^2-(4-mercapto-4-methyl-1-oxopentyl)-maytansine] via the reducible SPDB linker [*N*-succinimidyl 4-(2-pyridyldithio)butanoate]
For the *ravtansine* part, please refer to the document *"INN for pharmaceutical substances: Names for radicals, groups and others"**

coltuximab ravtansine

immunoglobuline G1-kappa, anti-[*Homo sapiens* CD19 (antigène de surface B4 des lymphocytes B, Leu-12)], anticorps monoclonal chimérique conjugué au maytansinoïde DM4;
chaîne lourde gamma1 (1-450) [*Mus musculus* VH (IGHV1-69*02 - (IGHD)-IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*01 (CH1 (121-218), charnière (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-211')-disulfure avec la chaîne légère kappa (1'-211') [*Mus musculus* V-KAPPA (IGKV4-70*01 - IGKJ1*01) [5.3.7] (1'-104') -*Homo sapiens* IGKC*01 (105'-211')]; dimère (229-229":232-232")-bisdisulfure; conjugué, sur 3 à 4 lysyl en moyenne, au maytansinoïde DM4 [N^2-déacétyl-N^2-(4-mercapto-4-méthyl-1-oxopentyl)-maytansine] via le linker SPDB réductible [4-(2-pyridyldithio)butanoate de *N*-succinimidyle]
Pour la partie *ravtansine*, veuillez-vous référer au document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

coltuximab ravtansina

inmunoglobulina G1-kappa, anti-[CD19 de *Homo sapiens* (antígeno de superficie B4 de los linfocitos B, Leu-12)], anticuerpo monoclonal quimérico conjugado con el maitansinoide DM4;
cadena pesada gamma1 (1-450) [*Mus musculus* VH (IGHV1-69*02 - (IGHD)-IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*01 (CH1 (121-218), bisagra (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-211')-disulfuro con la cadena ligera kappa (1'-211') [*Mus musculus* V-KAPPA (IGKV4-70*01 -IGKJ1*01) [5.3.7] (1'-104') -*Homo sapiens* IGKC*01 (105'-211')]; dímero (229-229":232-232")-bisdisulfuro;conjugado en 3 -4 restos lisil por término medio, con el maitansinoide DM4 [N^2-desacetil-N^2-(4-mercapto-4-metil-1-oxopentil)-maitansina] mediante un conector SPDB reducible [4-(2-piridilditio)butanoato de *N*-succinimidilo]
La información sobre la *ravtansina*, la encontrarán en el documento *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQPGAE VVKPGASVKL SCKTSGYTFT SNWMHWVKQA PGQGLEWIGE  50
IDPSDSYTNY NQNFQGKAKL TVDKSTSTAY MEVSSLRSDD TAVYYCARGS 100
NPYYYAMDYW GQGTSVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAI MSASPGERVT MTCSASSGVN YMHWYQQKPG TSPRRWIYDT  50
SKLASGVPAR FSGSGSGTDY SLTISSMEPE DAATYYCHQR GSYTFGGGTK 100
LEIKRTVAAP SVFIFPPSDE QLKSGTASVV CLLNNFYPRE AKVQWKVDNA 150
LQSGNSQESV TEQDSKDSTY SLSSTLTLSK ADYEKHKVYA CEVTHQGLSS 200
PVTKSFNRGE C                                           211
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	147-203	264-324	370-428
	22"-96"	147"-203"	264"-324"	370"-428"
Intra-L (C23-C104)	23'-87'	131'-191'		
	23'"-87'"	131'"-191'"		
Inter-H-L (h 5-CL 126)	223-211'	223"-211'"		
Inter-H-H (h 11, h 14)	229-229"	232-232"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
300, 300"
For the *ravtansine* part, please refer to the document *"INN for pharmaceutical substances: Names for radicals, groups and others"**
Pour la partie *ravtansine,* veuillez vous référer au document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*
Para la fracción *ravtansina,* se pueden dirigir al documento *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

damoctocogum alfa pegolum #

damoctocog alfa pegol

recombinant DNA derived pegylated B domain deleted human blood coagulation factor VIII (single protein chain) analogue, produced in BHK21 cells (glycoform alfa):
des-(743-1636)-[1804-[*S*-(1-{3-[(3-{2,3-bis[ω-methoxypoly(oxyethylene)]propoxy}propyl)amino]-3-oxopropyl}-2,5-dioxopyrrolidin-3-yl)-L-cysteine](K>C)]human coagulation factor VIII

damoctocog alfa pégol

analogue du facteur de coagulation sanguine VIII humain amputé du domaine B (une seule chaîne protéique), produit par des cellules BHK21 à partir d'ADN recombinant (glycoforme alfa) :
dès-(743-1636)-[1804-[*S*-(1-{3-[(3-{2,3-bis[ω-méthoxypoly(oxyéthylène)]propoxy}propyl)amino]-3-oxopropyl}-2,5-dioxopyrrolidin-3-yl)-L-cystéine](K>C)]facteur VIII de coagulation humain

damoctocog alfa pegol

análogo del factor VIII de coagulación humano privado del domanio B (una sola cadena proteica), producido por células BHK21 a partir de ADN recombinante (glicoforma alfa) :
des-(743-1636)-[1804-[*S*-(1-{3-[(3-{2,3-bis[ω-metoxipoli(oxietileno)]propoxi}propil)amino]-3-oxopropil}-2,5-dioxopirrolidin-3-il)-L-cisteina](K>C)]factor VIII de coagulación humano

Single chain protein / Protéine monocaténaire / Proteína monocatenaria (1438 AA)

```
ATRRYYLGAV ELSWDYMQSD LGELPVDARF PPRVPKSFPF NTSVVYKKTL 50
FVEFTDHLFN IAKPRPPWMG LLGPTIQAEV YDTVVITLKN MASHPVSLHA 100
VGVSYWKASE GAEYDDQTSQ REKEDDKVFP GGSHTYVWQV LKENGPMASD 150
PLCLTYSYLS HVDLVKDLNS GLIGALLVCR EGSLAKEKTQ TLHKFILLFA 200
VFDEGKSWHS ETKNSLMQDR DAASARAWPK MHTVNGYVNR SLPGLIGCHR 250
KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN HRQASLEISP ITFLTAQTLL 300
MDLGQFLLFC HISSHQHDGM EAYVKVDSCP EEPQLRMKNN EEAEDYDDDL 350
TDSEMDVVRF DDDNSPSFIQ IRSVAKKHPK TWVHYIAAEE EDWDYAPLVL 400
APDDRSYKSQ YLNNGPQRIG RKYKKVRFMA YTDETFKTRE AIQHESGILG 450
PLLYGEVGDT LLIIFKNQAS RPYNIYPHGI TDVRPLYSRR LPKGVKHLKD 500
FPILPGEIFK YKWTVTVEDG PTKSDPRCLT RYYSSFVNME RDLASGLIGP 550
LLICYKESVD QRGNQIMSDK RNVILFSVFD ENRSWYLTEN IQRFLPNPAG 600
VQLEDPEFQA SNIMHSINGY VFDSLQLSVC LHEVAYWYIL SIGAQTDFLS 650
VFFSGYTFKH KMVYEDTLTL FPFSGETVFM SMENPGLWIL GCHNSDFRNR 700
GMTALLKVSS CDKNTGDYYE DSYEDISAYL LSKNNAIEPR SF          742
                                        SQNP PVLKRHQREI 1650
TRTTLQSDQE EIDYDDTISV EMKKEDFDIY DEDENQSPRS FQKKTRHYFI 1700
AAVERLWDYG MSSSPHVLRN RAQSGSVPQF KKVVFQEFTD GSFTQPLYRG 1750
ELNEHLGLLG PYIRAEVEDN IMVTFRNQAS RPYSFYSSLI SYEEDQRQGA 1800
EPRCNFVKPN ETKTYFWKVQ HHMAPTKDEF DCKAWAYFSD VDLEKDVHSG 1850
LIGPLLVCHT NTLNPAHGRQ VTVQEFALFF TIFDETKSWY FTENMERNCR 1900
APCNIQMEDP TFKENYRFHA INGYIMDTLP GLVMAQDQRI RWYLLSMGSN 1950
ENIHSIHFSG HVFTVRKKEE YKMALYNLYP GVFETVEMLP SKAGIWRVEC 2000
LIGEHLHAGM STLFLVYSNK CQTPLGMASG HIRDFQITAS GQYGQWAPKL 2050
ARLHYSGSIN AWSTKEPFSW IKVDLLAPMI IHGIKTQGAR QKFSSLYISQ 2100
FIIMYSLDGK KWQTYRGNST GTLMVFFGNV DSSGIKHNIF NPPIIARYIR 2150
LHPTHYSIRS TLRMELMGCD LNSCSMPLGM ESKAISDAQI TASSYFTNMF 2200
ATWSPSKARL HLQGRSNAWR PQVNNPKEWL QVDFQKTMKV TGVTTQGVKS 2250
LLTSMYVKEF LISSSQDGHQ WTLFFQNGKV KVFQGNQDSF TPVVNSLDPP 2300
LLTRYLRIHP QSWVHQIALR MEVLGCEAQD LY                    2332
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
153-179 248-329 528-554 630-711 1832-1858 1899-1903 2021-2169 2174-2326

Modified residues / Résidus modifiés / Restos modificados



Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
Asn-41 Asn-239 Asn-1810 Asn-2118

dasabuvirum

dasabuvir — *N*-(6-{3-*tert*-butyl-5-[2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl]-2-methoxyphenyl}naphthalen-2-yl)methanesulfonamide

dasabuvir — *N*-(6-{3-*tert*-butyl-5-[2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl]-2-méthoxyphényl}naphtalén-2-yl)méthanesulfonamide

dasabuvir — *N*-(6-{3-*terc*-butil-5-[2,4-dioxo-3,4-dihidropirimidin-1(2*H*)-il]-2-metoxifenil}naftalen-2-il)metanosulfonamida

$C_{26}H_{27}N_3O_5S$



decoglurantum

decoglurant — 5-[2-[7-(trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-*a*]pyrimidin-3-yl]ethynyl]pyridin-2-amine

décoglurant — 5-(2-{7-(trifluorométhyl)-5-[4-(trifluorométhyl)phényl]pyrazolo[1,5-*a*]pyrimidin-3-yl}ethynyl)pyridin-2-amine

decoglurant — 5-(2-{7-(trifluorometil)-5-[4-(trifluorometil)fenil]pirazolo[1,5-*a*]pirimidin-3-il}etinil)piridin-2-amina

$C_{21}H_{11}F_6N_5$



dianexinum #

dianexin — recombinant DNA derived annexin A5 dimer covalently linked by a 14 residues peptide linker, produced in *Escherichia coli* (nonglycosylated):
L-methionyl-human annexin A5 fusion protein with glycyl-L-seryl-L-leucyl-L-α-glutamyl-L-valyl-L-leucyl-L-phenylalanyl-L-glutaminylglycyl-L-prolyl-L-serylglycyl-L-lysyl-L-leucyl-human annexin A5

dianexine — dimère de l'annexine A5 liées de façon covalente par une chaîne peptidique de 14 acides aminés, produit par *Escherichia coli* à partir d'ADN recombinant (non glycosylé) :
L-méthionyl-annexine A5 humaine protéine de fusion avec la glycyl-L-séryl-L-leucyl-L-α-glutamyl-L-valyl-L-leucyl-L-phénylalanyl-L-glutaminylglycyl-L-prolyl-L-sérylglycyl-L-lysyl-L-leucyl-annexine A5 humaine

dianexina

dímero de la anexina A5 covalentemente unido por una cadena peptídica de 14 aminoácidos, producido por *Escherichia coli* a partir de ADN recombinante (no glicosilado) :
L-metionil-anexina A5 humana proteína de fusión con la glicil-L-seril-L-leucil-L-α-glutamil-L-valil-L-leucil-L-fenilalanil-L-glutaminilglicil-L-prolil-L-serilglicil-L-lisil-L-leucil-anexina A5 humana

Sequence / Séquence / Secuencia

```
MAQVLRGTVT DFPGFDERAD AETLRKAMKG LGTDEESILT LLTSRSNAQR 50
QEISAAFKTL FGRDLLDDLK SELTGKFEKL IVALMKPSRL YDAYELKHAL 100
KGAGTNEKVL TEIIASRTPE ELRAIKQVYE EEYGSSLEDD VVGDTSGYYQ 150
RMLVVLLQAN RDPDAGIDEA QVEQDAQALF QAGELKWGTD EEKFITIFGT 200
RSVSHLRKVF DKYMTISGFQ IEETIDRETS GNLEQLLLAV VKSIRSIPAY 250
LAETLYYAMK GAGTDDHTLI RVMVSRSEID LFNIRKEFRK NFATSLYSMI 300
KGDTSGDYKK ALLLLCGEDD GSLEVLFQGP SGKLAQVLRG TVTDFPGFDE 350
RADAETLRKA MKGLGTDEES ILTLLTSRSN AQRQEISAAF KTLFGRDLLD 400
DLKSELTGKF EKLIVALMKP SRLYDAYELK HALKGAGTNE KVLTEIIASR 450
TPEELRAIKQ VYEEEYGSSL EDDVVGDTSG YYQRMLVVLL QANRDPDAGI 500
DEAQVEQDAQ ALFQAGELKW GTDEEKFITI FGTRSVSHLR KVFDKYMTIS 550
GFQIEETIDR ETSGNLEQLL LAVVKSIRSI PAYLAETLYY AMKGAGTDDH 600
TLIRVMVSRS EIDLFNIRKE FRKNFATSLY SMIKGDTSGD YKKALLLLCG 650
EDD                                                     653
```

Modified residues / Résidus modifiés / Restos modificados

K = N^6-acetylLys
70-76-79-97-101-403-409-412-430-434



Y = phosphoTyr
94-427



dinutuximabum #

dinutuximab

immunoglobulin G1-kappa, anti-ganglioside GD2, chimeric monoclonal antibody;
gamma1 heavy chain (1-443) [*Mus musculus* VH (IGHV1S135*01 -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -*Homo sapiens* IGHG1*03 (CH1 (114-211), hinge (212-226), CH2 (227-336), CH3 (337-441), CHS (442-443)) (114-443)], (216-220')-disulfide with kappa light chain (1'-220') [*Mus musculus* V-KAPPA (IGKV1-110*01 -IGKJ5*01) 11.3.10] (1'-113') -*Homo sapiens* IGKC*01 (114'-220')]; dimer (222-222":225-225")-bisdisulfide

dinutuximab

immunoglobuline G1-kappa, anti-ganglioside GD2, anticorps monoclonal chimérique;
chaîne lourde gamma1 (1-443) [*Mus musculus* VH (IGHV1S135*01 -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -*Homo sapiens* IGHG1*03 (CH1 (114-222), charnière (223-237), CH2 (238-347), CH3 (348-452), CHS (453-454)) (125-454)], (216-220')-disulfure avec la chaîne légère kappa (1'-220') [*Mus musculus* V-KAPPA (IGKV1-110*01 -IGKJ5*01) 11.3.10] (1'-113') -*Homo sapiens* IGKC*01 (114'-220')]; dimère (222-222":225-225")-bisdisulfure

dinutuximab

inmunoglobulina G1-kappa, anti-gangliósido GD2, anticuerpo monoclonal quimérico;
cadena pesada gamma1 (1-443) [*Mus musculus* VH (IGHV1S135*01 -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -*Homo sapiens* IGHG1*03 (CH1 (114-222), bisagra (223-237), CH2 (238-347), CH3 (348-452), CHS (453-454)) (125-454)], (216-220')-disulfuro con la cadena ligera kappa (1'-220') [*Mus musculus* V-KAPPA (IGKV1-110*01 -IGKJ5*01) 11.3.10] (1'-113') -*Homo sapiens* IGKC*01 (114'-220')]; dímero(222-222":225-225")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLLQSGPE LEKPGASVMI SCKASGSSFT GYNMNWVRQN IGKSLEWIGA  50
IDPYYGGTSY NQKFKGRATL TVDKSSSTAY MHLKSLTSED SAVYYCVSGM 100
EYWGQGTSVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC LVKDYFPEPV 150
TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG TQTYICNVNH 200
KPSNTKVDKR VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP PKPKDTLMIS 250
RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE QYNSTYRVVS 300
VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR EPQVYTLPPS 350
REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF 400
FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS PGK        443
```

Light chain / Chaîne légère / Cadena ligera

```
EIVMTQSPAT LSVSPGERAT LSCRSSQSLV HRNGNTYLHW YLQKPGQSPK  50
LLIHKVSNRF SGVPDRFSGS GSGTDFTLKI SRVEAEDLGV YFCSQSTHVP 100
PLTFGAGTKL ELKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150
KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC 200
EVTHQGLSSP VTKSFNRGEC                                   220
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	140-196	257-317	363-421
	22"-96"	140"-196"	257"-317"	363"-421"
Intra-L (C23-C104)	23'-93'	140'-200'		
	23'"-93'"	140'"-200'"		
Inter-H-L (h 5-CL 126)	216-220'	216"-220'"		
Inter-H-H (h 11-h 14)	222-222"	225-225"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
293, 293"

doravirinum

doravirine — 3-chloro-5-({1-[(4-methyl-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl}oxy)benzonitrile

doravirine — 3-chloro-5-({1-[(4-méthyl-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)méthyl]-2-oxo-4-(trifluorométhyl)-1,2-dihydropyridin-3-yl}oxy)benzonitrile

doravirina — 3-cloro-5-({1-[(4-metil-5-oxo-4,5-dihidro-1*H*-1,2,4-triazol-3-il)metil]-2-oxo-4-(trifluorometil)-1,2-dihidropiridin-3-il}oxi)benzonitrilo

$C_{17}H_{11}ClF_3N_5O_3$



eldelumabum #

eldelumab — immunoglobulin G1-kappa, anti-[*Homo sapiens* CXCL10 (chemokine C-X-C motif ligand 10, 10 kDa interferon gamma-induced protein gamma-IP10, IP-10, INP10, small inducible cytokine B10, SCYB10)], *Homo sapiens* monoclonal antibody;gamma1 heavy chain (1-454) [*Homo sapiens* VH (IGHV3-33*01 (89.80%) -(IGHD)-IGHJ6*01) [8.8.17] (1-124) -IGHG1*01 (CH1 (125-222), hinge (223-237), CH2 (238-347), CH3 (348-452), CHS (453-454)) (125-454)], (227-216')-disulfide with kappa light chain (1'-216') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ3*01) [7.3.10] (1'-109') -IGKC*01 (110'-216')]; dimer (233-233":236-236")-bisdisulfide

eldélumab	immunoglobuline G1-kappa, anti-[*Homo sapiens* CXCL10 (chémokine C-X-C motif ligand 10, protéine gamma-IP10 de 10 kDa induite par l'interféron gamma, IP-10, INP10, petite cytokine inductible B10, SCYB10)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-454) [*Homo sapiens* VH (IGHV3-33*01 (89.80%) -(IGHD)-IGHJ6*01) [8.8.17] (1-124) -IGHG1*01 (CH1 (125-222), charnière (223-237), CH2 (238-347), CH3 (348-452), CHS (453-454)) (125-454)], (227-216')-disulfure avec la chaîne légère kappa (1'-216') [*Homo sapiens* V- KAPPA (IGKV3-20*01 (100.00%) -IGKJ3*01) [7.3.10] (1'-109') -IGKC*01 (110'-216')]; dimère (233-233'':236-236'')-bisdisulfure
eldelumab	inmunoglobulina G1-kappa, anti-[CXCL10 de *Homo sapiens* (quimioquina C-X-C motivo ligando 10, proteína gamma-IP10 de 10 kDa inducida por el interferón gamma, IP-10, INP10, pequeña citoquina inducible B10, SCYB10)], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma1 (1-454) [*Homo sapiens* VH (IGHV3-33*01 (89.80%) -(IGHD)-IGHJ6*01) [8.8.17] (1-124) -IGHG1*01 (CH1 (125-222), bisagra (223-237), CH2 (238-347), CH3 (348-452), CHS (453-454)) (125-454)], (227-216')-disulfuro con la cadena ligera kappa (1'-216') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ3*01) [7.3.10] (1'-109') -IGKC*01 (110'-216')]; dimero (233-233'':236-236'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QMQLVESGGG VVQPGRSLRL SCTASGFTFS NNGMHWVRQA PGKGLEWVAV  50
IWFDGMNKFY VDSVKGRFTI SRDNSKNTLY LEMNSLRAED TAIYYCAREG 100
DGSGIYYYYG MDVWGQGTTV TVSSASTKGP SVFPLAPSSK STSGGTAALG 150
CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL 200
GTQTYICNVN HKPSNTKVDK RVEPKSCDKT HTCPPCPAPE LLGGPSVFLF 250
PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE 300
EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP 350
REPQVYTLPP SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT 400
TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL 450
SPGK                                                    454
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPGT LSLSPGERAT LSCRASQSVS SSYLAWYQQK PGQAPRLLIY  50
GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSSPIFTF 100
GPGTKVDIKR TVAAPSVFIF PPSDEQLKSG TASVVCLLNN FYPREAKVQW 150
KVDNALQSGN SQESVTEQDS KDSTYSLSST LTLSKADYEK HKVYACEVTH 200
QGLSSPVTKS FNRGEC                                      216
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H (C23-C104)  22-96    151-207   268-328   374-432
                    22"-96"  151"-207" 268"-328" 374"-432"
Intra-L (C23-C104)  23'-89'   136'-196'
                    23'"-89'" 136'"-196'"
Inter-H-L (h 5-CL 126)  227-216'  227"-216'"
Inter-H-H (h 11, h 14)  233-233"  236-236"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
304, 304"

eluxadolinum

eluxadoline	5-({[(2*S*)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)propanoyl][(1*S*)-1-(4-phenyl-1*H*-imidazol-2-yl)ethyl]amino}methyl)-2-methoxybenzoic acid
éluxadoline	acide 5-({[(2*S*)-2-amino-3-(4-carbamoyl-2,6-diméthylphényl)propanoyl][(1*S*)-1-(4-phényl-1*H*-imidazol-2-yl)éthyl]amino}méthyl)-2-méthoxybenzoïque
eluxadolina	ácido 5-({[(2*S*)-2-amino-3-(4-carbamoil-2,6-dimetilfenil)propanoil][(1*S*)-1-(4-fenil-1*H*-imidazol-2-il)etil]amino}metil)-2-metoxibenzoico

$C_{32}H_{35}N_5O_5$



encorafenibum

encorafenib — methyl *N*-{(*2S*)-1-[(4-{3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]}-1-(propan-2-yl)-1*H*-pyrazol-4-yl}pyrimidin-2-yl)amino]propan-2-yl}carbamate

encorafénib — *N*-{(*2S*)-1-[(4-{3-[5-chloro-2-fluoro-3-(méthanesulfonamido)phényl]}-1-(propan-2-yl)-1*H*-pyrazol-4-yl}pyrimidin-2-yl)amino]propan-2-yl}carbamate de méthyle

encorafenib — *N*-{(*2S*)-1-[(4-{3-[5-cloro-2-fluoro-3-(metanosulfonamido)fenil]}-1-(propan-2-il)-1*H*-pirazol-4-il}pirimidin-2-il)amino]propan-2-il}carbamato de metilo

$C_{22}H_{27}ClFN_7O_4S$



enfortumabum vedotinum #

enfortumab vedotin — immunoglobulin G1-kappa, anti-[*Homo sapiens* PVRL4 (poliovirus receptor-related 4, nectin-4, nectin 4, PPR4, LNIR], *Homo sapiens* monoclonal antibody conjugated to auristatin E;
gamma1 heavy chain (1-447) [*Homo sapiens* VH (IGHV3-48*02 (98.00%) -(IGHD)-IGHJ6*01) [8.8.10] (1-117) -IGHG1*03 (CH1 (118-215), hinge (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-12*01 (96.80%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer (226-226'':229-229'')-bisdisulfide; conjugated, on an average of 3 to 4 cysteinyl, to monomethylauristatin E (MMAE), via a cleavable maleimidecaproyl-valyl-citrullinyl-*p*-aminobenzylcarbamate (mc-val-cit-PABC) linker
For the *vedotin* part, please refer to the document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

enfortumab védotine

immunoglobuline G1-kappa, anti-[*Homo sapiens* PVRL4 (membre 4 de la famille du récepteur du poliovirus, nectine-4, nectine 4, PPR4, LNIR], *Homo sapiens* anticorps monoclonal conjugué à l'auristatine E; chaîne lourde gamma1 (1-447) [*Homo sapiens* VH (IGHV3-48*02 (98.00%) -(IGHD)-IGHJ6*01) [8.8.10] (1-117) -IGHG1*03 (CH1 (118-215), charnière (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V- KAPPA (IGKV1-12*01 (96.80%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (226-226'':229-229'')-bisdisulfure; conjugué, sur 3 à 4 cystéinyl en moyenne, au monométhylauristatine E (MMAE), via un linker clivable maléimidecaproyl-valyl-citrullinyl-*p*-aminobenzylcarbamate (mc-val-cit-PABC)
Pour la partie *védotine*, veuillez-vous référer au document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

enfortumab vedotina

inmunoglobulina G1-kappa, anti-[PVRL4 de *Homo sapiens* (miembro 4 de la familia del receptor de poliovirus, nectina-4, nectina 4, PPR4, LNIR], anticuerpo monoclonal de *Homo sapiens* conjugado con auristatina E;
cadena pesada gamma1 (1-447) [*Homo sapiens* VH (IGHV3-48*02 (98.00%) -(IGHD)-IGHJ6*01) [8.8.10] (1-117) -IGHG1*03 (CH1 (118-215), bisagra(216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-12*01 (96.80%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (226-226'':229-229'')-bisdisulfuro; conjugado, en 3- 4 restos cisteinil por término medio, con monometilauristatinea E (MMAE), mediante un conector escindible maleimidocaproil-valil-citrulinil-*p*-aminobencilcarbamato (mc-val-cit-PABC)
La información sobre la *vedotina*, la encontrarán en el documento *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYNMNWVRQA PGKGLEWVSY  50
ISSSSSTIYY ADSVKGRFTI SRDNAKNSLS LQMNSLRDED TAVYYCARAY 100
YYGMDVWGQG TTVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK    447
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS VSASVGDRVT ITCRASQGIS GWLAWYQQKP GKAPKFLIYA  50
ASTLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ ANSFPPTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 144-200 261-321 367-425
22"-96" 144"-200" 261"-321" 367"-425"
Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L (h 5-CL 126) * 220-214' 220"-214'"
Inter-H-H (h 11, h 14) * 226-226" 229-229"
*Two or three of the inter-chain disulfide bridges are not present, an average of 3 to 4 cysteinyl being conjugated each to a drug linker.
*Deux ou trois des ponts disulfures inter-chaînes ne sont pas présents, 3 à 4 cystéinyl en moyenne étant chacun conjugué à un linker-principe actif.
*Faltan dos o tres puentes disulfuro inter-catenarios, una media de 3 a 4 cisteinil está conjugada a conectores de principio activo.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
297, 297"

For the vedotin part, please refer to the document "INN for pharmaceutical substances: Names for radicals, groups and others"*

Pour la partie védotine, veuillez vous référer au document "INN for pharmaceutical substances: Names for radicals, groups and others"*.

Para la fracción vedotina, se pueden dirigir al documento "INN for pharmaceutical substances: Names for radicals, groups and others"*.

fevipiprantum

fevipiprant — 2-(1-{[4-methanesulfonyl-2-(trifluoromethyl)phenyl]methyl}-2-methyl-1*H*-pyrrolo[2,3-*b*]pyridin-3-yl)acetic acid

févipiprant — acide 2-(1-{[4-méthanesulfonyl-2-(trifluorométhyl)phényl]méthyl}-2-méthyl-1*H*-pyrrolo[2,3-*b*]pyridin-3-yl)acétique

fevipiprant — ácido 2-(1-{[4-metanosulfonil-2-(trifluorometil)fenil]metil}-2-metil-1*H*-pirrolo[2,3-*b*]piridin-3-il)acético

$C_{19}H_{17}F_3N_2O_4S$



filanesibum

filanesib — (2*S*)-2-(3-aminopropyl)-5-(2,5-difluorophenyl)-*N*-methoxy-*N*-methyl-2-phenyl-1,3,4-thiadiazole-3(2*H*)-carboxamide

filanésib — (2*S*)-2-(3-aminopropyl)-5-(2,5-difluorophényl)-*N*-méthoxy-*N*-méthyl-2-phényl-1,3,4-thiadiazole-3(2*H*)-carboxamide

filanesib — (2*S*)-2-(3-aminopropil)-5-(2,5-difluorofenil)-2-fenil-*N*-metil-*N*-metoxi-1,3,4-tiadiazol-3(2*H*)-carboxamida

$C_{20}H_{22}F_2N_4O_2S$



galunisertibum

galunisertib — 4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4*H*-pyrrolo[1,2-*b*]pyrazol-3-yl]quinoline-6-carboxamide

galunisertib — 4-[2-(6-méthylpyridin-2-yl)-5,6-dihydro-4*H*-pyrrolo[1,2-*b*]pyrazol-3-yl]quinoléine-6-carboxamide

galunisertib — 4-[2-(6-metilpiridin-2-il)-5,6-dihidro-4*H*-pirrolo[1,2-*b*]pirazol-3-il]quinolina-6-carboxamida

$C_{22}H_{19}N_5O$



guselkumabum #

guselkumab

immunoglobulin G1-lambda2, anti-[*Homo sapiens* IL23 (interleukin 23, IL-23)], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-446) [*Homo sapiens* VH (IGHV5-51*01 (93.90%) -(IGHD)-IGHJ3*01 M123>L (112)) [8.8.10] (1-117) -IGHG1*01 (CH1 (118-215), hinge (216-230), CH2 (231-340), CH3 (341-444), CHS (445-446)) (118-446)], (220-216')-disulfide with lambda light chain (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-40*01 (91.80%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dimer (226-226'':229-229'')-bisdisulfide

guselkumab

immunoglobuline G1-lambda2, anti-[*Homo sapiens* IL23 (interleukine 23, IL-23)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-446) [*Homo sapiens* VH (IGHV5-51*01 (93.90%) -(IGHD)-IGHJ3*01 M123>L (112)) [8.8.10] (1-117) -IGHG1*01 (CH1 (118-215), charnière (216-230), CH2 (231-340), CH3 (341-444), CHS (445-446)) (118-446)], (220-216')-disulfure avec la chaîne légère lambda (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-40*01 (91.80%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dimère (226-226'':229-229'')-bisdisulfure

guselkumab

inmunoglobulina G1-lambda2, anti-[IL23 (interleukina 23, IL-23) de *Homo sapiens*], anticuerpo monoclonal de *Homo sapiens*;
cadena pesada gamma1 (1-446) [*Homo sapiens* VH (IGHV5-51*01 (93.90%) -(IGHD)-IGHJ3*01 M123>L (112)) [8.8.10] (1-117) -IGHG1*01 (CH1 (118-215), bisagra (216-230), CH2 (231-340), CH3 (341-444), CHS (445-446)) (118-446)], (220-216')-disulfuro con la cadena ligera lambda (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-40*01 (91.80%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dímero (226-226'':229-229'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVQSGAE VKKPGESLKI SCKGSGYSFS NYWIGWVRQM PGKGLEWMGI  50
IDPSNSYTRY SPSFQGQVTI SADKSISTAY LQWSSLKASD TAMYYCARWY 100
YKPFDVWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPG     446
```

Light chain / Chaîne légère / Cadena ligera

```
QSVLTQPPSV SGAPGQRVTI SCTGSSSNIG SGYDVHWYQQ LPGTAPKLLI  50
YGNSKRPSGV PDRFSGSKSG TSASLAITGL QSEDEADYYC ASWTDGLSLV 100
VFGGGTKLTV LGQPKAAPSV TLFPPSSEEL QANKATLVCL ISDFYPGAVT 150
VAWKADSSPV KAGVETTTPS KQSNNKYAAS SYLSLTPEQW KSHRSYSCQV 200
THEGSTVEKT VAPTECS                                     217
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	144-200	261-321	367-425
	22''-96''	144''-200''	261''-321''	367''-425''
Intra-L (C23-C104)	22'-90'	139'-198'		
	22'''-90'''	139'''-198'''		
Inter-H-L (h 5-CL 126)	220-216'	220''-216'''		
Inter-H-H (h 11, h 14)	226-226''	229-229''		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
297, 297''

idarucizumabum #

idarucizumab

immunoglobulin Fab G1-kappa, anti-[dagibatran], humanized monoclonal antibody;
VH-(CH1-hinge) gamma1 heavy chain (1-225) [humanized VH (*Homo sapiens* IGHV4-59*01 (82.30%) -(IGHD)-IGHJ4*01) [8.7.16] (1-122) -*Homo sapiens* IGHG1*01 (CH1 (123-220), hinge 1-5 (221-225)) (123-225)], (225-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV2-30*01 (88.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]

idarucizumab

immunoglobuline Fab G1-kappa, anti-[dagibatran], anticorps monoclonal humanisé;
chaîne lourde VH-(CH1-charnière) gamma1 (1-225) [VH humanisé (*Homo sapiens* IGHV4-59*01 (82.30%) -(IGHD)-IGHJ4*01) [8.7.16] (1-122) -*Homo sapiens* IGHG1*01 (CH1 (123-220), charnière 1-5 (221-225)) (123-225)], (225-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV2-30*01 (88.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]

idarucizumab

inmunoglobulina Fab G1-kappa, anti-[dagibatrán], anticuerpo monoclonal humanizado;
cadena pesada VH-(CH1-bisagra) gamma1 (1-225) [VH humanizado (*Homo sapiens* IGHV4-59*01 (82.30%) -(IGHD)-IGHJ4*01) [8.7.16] (1-122) -*Homo sapiens* IGHG1*01 (CH1 (123-220), bisagra 1-5 (221-225)) (123-225)], (225-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (*Homo sapiens* IGKV2-30*01 (88.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQESGPG LVKPSETLSL TCTVSGFSLT SYIVDWIRQP PGKGLEWIGV  50
IWAGGSTGYN SALRSRVSIT KDTSKNQFSL KLSSVTAADT AVYYCASAAY 100
YSYYNYDGFA YWGQGTLVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200
QTYICNVNHK PSNTKVDKKV EPKSC                            225
```

Light chain / Chaîne légère / Cadena ligera

```
DVVMTQSPLS LPVTLGQPAS ISCKSSQSLL YTDGKTYLYW FLQRPGQSPR  50
RLIYLVSKLD SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCLQSTHFP 100
HTFGGGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-95 149-205
Intra-L (C23-C104) 23'-93' 139'-199'
Inter-H-L (h 5-CL 126) 225-219'

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
None - Aucun - Ninguno

ipafriceptum #
ipafricept

fusion protein for immune applications (FPIA) comprising *Homo sapiens* FZD8 (frizzled family receptor 8, Frizzled-8) extracellular domain, fused with *Homo sapiens* immunoglobulin G1 Fc fragment; *Homo sapiens* FZD8 precursor fragment 28-158 (1-131) -*Homo sapiens* IGHG1*01 H-CH2-CH3 fragment (hinge 1-15 C5>S (136) (132-146), CH2 (147-256), CH3 (257-361), CHS (362-363)) (132-363); dimer (142-142':145-145')-bisdisulfide

ipafricept

protéine de fusion pour applications immunitaires (FPIA) comprenant le domaine extracellulaire d'*Homo sapiens* FZD8 (membre 8 de la famille de récepteurs frizzled, Frizzled-8), fusionné au fragment Fc de l'*Homo sapiens* immunoglobuline G1;
Homo sapiens FZD8 fragment 28-158 du précurseur (1-131) -*Homo sapiens* IGHG1*01 fragment H-CH2-CH3 (charnière 1-15 C5>S (136) (132-146), CH2 (147-256), CH3 (257-361), CHS (362-363)) (132-363); dimère (142-142':145-145')-bisdisulfure

ipafricept

proteína de fusión para aplicaciones inmunitarias (que comprende el dominio extracelular de FZD8 de *Homo sapiens* (miembro 8 de la familia de receptores frizzled, Frizzled-8), fusionado con el fragmento Fc de inmunoglobulina G1 de *Homo sapiens*; fragmento precursor 28-158 (1-131) de FZD8 de *Homo sapiens* - *Homo sapiens* IGHG1*01 fragmento H-CH2-CH3 (bisagra 1-15 C5>S (136) (132-146), CH2 (147-256), CH3 (257-361), CHS (362-363)) (132-363); dímero(142-142':145-145')-bisdisulfuro

Fused chain / chaine fusionnée / cadena fusionada

```
ASAKELACQE ITVPLCKGIG YNYTYMPNQF NHDTQDEAGL EVHQFWPLVE  50
IQCSPDLKFF LCSMYTPICL EDYKKPLPPC RSVCERAKAG CAPLMRQYGF 100
AWPDRMRCDR LPEQGNPDTL CMDYNRTDLT TEPKSSDKTH TCPPCPAPEL 150
LGGPSVFLFP PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV 200
HNAKTKPREE QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK 250
TISKAKGQPR EPQVYTLPPS RDELTKNQVS LTCLVKGFYP SDIAVEWESN 300
GQPENNYKTT PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN 350
HYTQKSLSLS PGK                                        363
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intrachain	FZD8	8-69 16-62 53-91 80-121 84-108
		8'-69' 16'-62' 53'-91' 80'-121' 84'-108'
	C23-C104	177-237 283-341
		177'-237' 283'-341'
Interchain	h 11, h 14	142-142' 145-145'

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
22, 125, 22', 125': bi-, tri- and tetra-antennary oligosaccharides containing up to 4 sialic acids
213, 213' (CH2 N84.4): complex biantennary oligosaccharide

Post-translational modifications/ modifications post-traductionnelles / modificaciones post-traduccionales
363, 363': C-terminal K processed by carboxypeptidase-like activity

ledipasvirum

ledipasvir

methyl [(1*S*)-1-{(1*R*,3*S*,4*S*)-3-[5-(9,9-difluoro-7-{2-[(6*S*)-5-{(2*S*)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-5-azaspiro[2.4]hept-6-yl]-1*H*-imidazol-4-yl}-9*H*-fluoren-2-yl)-1*H*-benzimidazol-2-yl]-2-azabicyclo[2.2.1]heptane-2-carbonyl}-2-methylpropyl]carbamate

lédipasvir

[(1*S*)-1-{(1*R*,3*S*,4*S*)-3-[5-(9,9-difluoro-7-{2-[(6*S*)-5-{(2*S*)-2-[(méthoxycarbonyl)amino]-3-méthylbutanoyl}-5-azaspiro[2.4]hept-6-yl]-1*H*-imidazol-4-yl}-9*H*-fluorén-2-yl)-1*H*-benzimidazol-2-yl]-2-azabicyclo[2.2.1]heptane-2-carbonyl}-2-méthylpropyl]carbamate de méthyle

ledipasvir

[(1*S*)-1-{(1*R*,3*S*,4*S*)-3-[5-(9,9-difluoro-7-{2-[(6*S*)-5-{(2*S*)-2-[(metoxicarbonil)amino]-3-metilbutanoil}-5-azaespiro[2.4]hept-6-il]-1*H*-imidazol-4-yl}-9*H*-fluoren-2-il)-1*H*-benzimidazol-2-il]-2-azabiciclo[2.2.1]heptano-2-carbonil}-2-metilpropil]carbamato de metilo

$C_{49}H_{54}F_2N_8O_6$



lexanopadolum

lexanopadol — *trans*-6'-fluoro-*N*-methyl-4-phenyl-4',9'-dihydro-3'*H*-spiro[cyclohexane-1,1'-pyrano[3,4-*b*]indol]-4-amine

lexanopadol — *trans*-6'-fluoro-*N*-méthyl-4-phényl-4',9'-dihydro-3'*H*-spiro[cyclohexane-1,1'-pyrano[3,4-*b*]indol]-4-amine

lexanopadol — *trans*-6'-fluoro-*N*-metil-4-fenil-4',9'-dihidro-3'*H*-espiro[ciclohexano-1,1'-pirano[3,4-*b*]indol]-4-amina

$C_{23}H_{25}FN_2O$



liafensinum

liafensine — 6-[(4*S*)-2-methyl-4-(naphthalen-2-yl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine

liafensine — 6-[(4*S*)-2-méthyl-4-(naphtalén-2-yl)-1,2,3,4-tétrahydroisoquinolin-7-yl]pyridazin-3-amine

liafensina — 6-[(4*S*)-2-metil-4-(naftalen-2-il)-1,2,3,4-tetrahidroisoquinolin-7-il]piridazin-3-amina

$C_{24}H_{22}N_4$



margetuximabum #

margetuximab — immunoglobulin G1-kappa, anti-[*Homo sapiens* ERBB2 (epidermal growth factor receptor 2, HER-2, p185c-erbB2, NEU, EGFR2)], chimeric monoclonal antibody;
gamma1 heavy chain (1-450) [*Mus musculus* VH (IGHV14-3*02 - (IGHD)-IGHJ4*01) [8.8.13] (1-120) - *Homo sapiens* IGHG1*01 (CH1 K120>R (217) (121-218), hinge (219-233), CH2 L1.2>V (238), F7>L (246), R83>P (295), Y85.2>L (303) (234-343), CH3 P83>L (399) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with kappa light chain (1'-214') [*Mus musculus* V-KAPPA (IGKV6-17*01 - IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimer (229-229":232-232")-bisdisulfide

margétuximab

immunoglobuline G1-kappa, anti-[*Homo sapiens* ERBB2 (récepteur 2 du facteur de croissance épidermique, HER-2, p185c-erbB2, NEU, EGFR2)], anticorps monoclonal chimérique;
chaîne lourde gamma1 (1-450) [*Mus musculus* VH (IGHV14-3*02 - (IGHD)-IGHJ4*01) [8.8.13] (1-120) - *Homo sapiens* IGHG1*01 (CH1 K120>R (217) (121-218), charnière (219-233), CH2 L1.2>V (238), F7>L (246), R83>P (295), Y85.2>L (303) (234-343), CH3 P83>L (399) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfure avec la chaîne légère kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV6-17*01 -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimère (229-229":232-232")-bisdisulfure

margetuximab

inmunoglobulina G1-kappa, anti-[ERBB2 de *Homo sapiens* (receptor 2 del factor de crecimiento epidérmico, HER-2, p185c-erbB2, NEU, EGFR2)], anticuerpo monoclonal quimérico;
cadena pesada gamma1 (1-450) [*Mus musculus* VH (IGHV14-3*02 - (IGHD)-IGHJ4*01) [8.8.13] (1-120) - *Homo sapiens* IGHG1*01 (CH1 K120>R (217) (121-218),bisagra (219-233), CH2 L1.2>V (238), F7>L (246), R83>P (295), Y85.2>L (303) (234-343), CH3 P83>L (399) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfuro con la cadena ligera kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV6-17*01 -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dímero (229-229":232-232")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQQSGPE LVKPGASLKL SCTASGFNIK DTYIHWVKQR PEQGLEWIGR  50
IYPTNGYTRY DPKFQDKATI TADTSSNTAY LQVSRLTSED TAVYYCSRWG 100
GDGFYAMDYW GQGASVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKRVEP KSCDKTHTCP PCPAPELVGG PSVFLLPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPPEEQYN 300
STLRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPLV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQSHKF MSTSVGDRVS ITCKASQDVN TAVAWYQQKP GHSPKLLIYS  50
ASFRYTGVPD RFTGSRSGTD FTFTISSVQA EDLAVYYCQQ HYTTPPTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	147-203	264-324	370-428
	22"-96"	147"-203"	264"-324"	370"-428"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (h 5-CL 126)	223-214'	223"-214'"		
Inter-H-H (h 11, h 14)	229-229"	232-232"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
300, 300"

mavatrepum

mavatrep

2-[2-(2-{(1*E*)-2-(trifluoromethyl)phenyl]ethenyl}-1*H*-benzimidazol-5-yl)phenyl]propan-2-ol

mavatrep

2-[2-(2-{(1*E*)-2-(trifluorométhyl)phényl]éthényl}-1*H*-benzimidazol-5-yl)phényl]propan-2-ol

mavatrep

2-[2-(2-{(1*E*)-2-(trifluorometil)fenil]etenil}-1*H*-benzoimidazol-5-il)fenil]propan-2-ol

$C_{25}H_{21}F_3N_2O$



methylsamidorphani chloridum

methylsamidorphan chloride	(17*R*)-3-carbamoyl-17-(cyclopropylmethyl)-4,14-dihydroxy-17-methyl-6-oxomorphinan-17-ium chloride
chlorure de méthylsamidorphan	chlorure de (17*R*)-3-carbamoyl-17-(cyclopropylméthyl)-4,14-dihydroxy-17-méthyl-6-oxomorphinanium
cloruro de metilsamidorfano	cloruro de (17*R*)-3-carbamoil-17-(ciclopropilmetil)-4,14-dihidroxi-17-metil-6-oxomorfinanio

$C_{22}H_{29}ClN_2O_4$



mirogabalinum

mirogabalin	[(1*R*,5*S*,6*S*)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid
mirogabaline	acide [(1*R*,5*S*,6*S*)-6-(aminométhyl)-3-éthylbicyclo[3.2.0]hept-3-én-6-yl]acétique
mirogabalina	ácido 2-[(1*R*,5*S*,6*S*)-6-(aminometil)-3-etilbiciclo[3.2.0]hept-3-en-6-il]acético

$C_{12}H_{19}NO_2$



neboterminum #

nebotermin	recombinant DNA derived L-methionyl-human bone morphogenetic protein 2 (BMP-2 or BMP-2A), produced in *Escherichia coli* (nonglycosylated)
nébotermine	L-méthionyl-protéine 2 morphogénétique de l'os humaine (BMP-2 ou BMP-2A), produite par *Escherichia coli* (non glycosylée) à partir d'ADN recombinant
nebotermina	L-metionil-proteína 2 morfogenética humana de hueso (BMP-2 o BMP-2A), producida por *Escherichia coli* (no glicosilada) a partir de ADN recombinante

$C_{1152}H_{1776}N_{322}O_{330}S_{20}$

Monomer / Monomère / Monómero

```
                                                                  M
QAKHKQRKRL KSSCKRHPLY VDFSDVGWND WIVAPPGYHA FYCHGECPFP 50
LADHLNSTNH AIVQTLVNSV NSKIPKACCV PTELSAISML YLDENEKVVL 100
KNYQDMVVEG CGCR                                          114
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
14-79 14'-79' 43-111 43'-111' 47-113 47'-113' 78-78'

nobiprostolanum

nobiprostolan — propan-2-yl (5*E*)-7-{(1*R*,2*R*,3*R*,5*S*)-2-[2-(2-heptyl-1,3-dioxolan-2-yl)ethyl]-3,5-dihydroxycyclopentyl}hept-5-enoate

nobiprostolan — (5*E*)-7-{(1*R*,2*R*,3*R*,5*S*)-2-[2-(2-heptyl-1,3-dioxolan-2-yl)éthyl]-3,5-dihydroxycyclopentyl}hept-5-énoate de propan-2-yle

nobiprostolán — (5*E*)-7-{(1*R*,2*R*,3*R*,5*S*)-2-[2-(2-heptil-1,3-dioxolan-2-il)etil]-3,5-dihidroxiciclopentil}hept-5-enoato de propan-2-ilo

$C_{27}H_{48}O_6$



ombitasvirum

ombitasvir — dimethyl *N*,*N*′-{[(2*S*,5*S*)-1-(4-*tert*-butylphenyl)pyrrolidene-2,5-diyl]-bis-{[(4,1-phenyleneazanediyl)carbonyl][(2*S*)-pyrrolidine-2,1-diyl]}[(2*S*)-3-methyl-1-oxobutane-1,2-diyl])}biscarbamate

ombitasvir — *N*,*N*′-{[(2*S*,5*S*)-1-(4-*tert*-butylphényl)pyrrolidine-2,5-diyl]-bis-{[(4,1-phénylèneazanediyl)carbonyl][(2*S*)-pyrrolidine-2,1-diyl]}[(2*S*)-3-méthyl-1-oxobutane-1,2-diyl])}biscarbamate de diméthyle

ombitasvir — *N*,*N*′-{[(2*S*,5*S*)-1-(4-*terc*-butilfenil)pirrolideno-2,5-diil]-bis-{[(4,1-fenilenoazanodiil)carbonil][(2*S*)-pirrolidina-2,1-diil]}[(2*S*)-3-metil-1-oxobutano-1,2-diil])}biscarbamato de dimetilo

$C_{50}H_{67}N_7O_8$



ontuxizumabum #

ontuxizumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CD248 (endosialin, tumor endothelial marker 1, TEM1), humanized/chimeric monoclonal antibody;
gamma1 heavy chain (1-454) [chimeric VH (*Homo sapiens* IGHV4-59*04 (68.00%) -(IGHD)-IGHJ4*01) [8.8.17] (1-124) -*Homo sapiens* IGHG1*01 (CH1 (125-222), hinge (223-237), CH2 (238-347), CH3 S85.3>F (410) (348-452), CHS (453-454)) (125-454)], (227-215')-disulfide with kappa light chain (1'-215') [humanized V-KAPPA (*Homo sapiens* IGKV1-33*01 (83.20%) -IGKJ1*01) [6.3.10] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')]; dimer (233-233'':236-236'')-bisdisulfide

ontuxizumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* CD248 (endosialine, marqueur endothélial tumoral 1, TEM1)], anticorps monoclonal humanisé/chimérique;
chaîne lourde gamma1 (1-454) [VH chimérique (*Homo sapiens* IGHV4-59*04 (68.00%) -(IGHD)-IGHJ4*01) [8.8.17] (1-124) -*Homo sapiens* IGHG1*01 (CH1 (125-222), charnière (223-237), CH2 (238-347), CH3 S85.3>F (410) (348-452), CHS (453-454)) (125-454)], (227-215')-disulfure avec la chaîne légère kappa (1'-215') [V-KAPPA humanisé (*Homo sapiens* IGKV1-33*01 (83.20%) -IGKJ1*01) [6.3.10] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')]; dimère (233-233'':236-236'')-bisdisulfure

ontuxizumab

inmunoglobulina G1-kappa, anti-[CD248 de *Homo sapiens* (endosialina, marcador endotelial tumoral 1, TEM1)], anticuerpo monoclonal humanizado/quimérico;
cadena pesada gamma1 (1-454) [VH quimérico (*Homo sapiens* IGHV4-59*04 (68.00%) -(IGHD)-IGHJ4*01) [8.8.17] (1-124) -*Homo sapiens* IGHG1*01 (CH1 (125-222), bisagra (223-237), CH2 (238-347), CH3 S85.3>F (410) (348-452), CHS (453-454)) (125-454)], (227-215')-disulfuro con la cadena ligera kappa (1'-215') [V-KAPPA humanizada (*Homo sapiens* IGKV1-33*01 (83.20%) -IGKJ1*01) [6.3.10] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')]; dímero (233-233'':236-236'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQESGPG LVRPSQTLSL TCTASGYTFT DYVIHWVKQP PGRGLEWIGY  50
INPYDDDTTY NQKFKGRVTM LVDTSSNTAY LRLSSVTAED TAVYYCARRG 100
NSYDGYFDYS MDYWGSGTPV TVSSASTKGP SVFPLAPSSK STSGGTAALG 150
CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL 200
GTQTYICNVN HKPSNTKVDK KVEPKSCDKT HTCPPCPAPE LLGGPSVFLF 250
PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE 300
EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP 350
REPQVYTLPP SRDELTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT 400
TPPVLDSDGF FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL 450
SPGK                                                    454
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRASQNVG TAVAWLQQTP GKAPKLLIYS  50
ASNRYTGVPS RFSGSGSGTD YTFTISSLQP EDIATYYCQQ YTNYPMYTFG 100
QGTKVQIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC                                        215
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	151-207	268-328	374-432
	22"-96"	151"-207"	268"-328"	374"-432"
Intra-L (C23-C104)	23'-88'	135'-195'		
	23'"-88'"	135'"-195'"		
Inter-H-L (h 5-CL 126)	227-215'	227"-215'"		
Inter-H-H (h 11, h 14)	233-233"	236-236"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
304, 304"

oreptacogum alfa (activatum) #

oreptacog alfa (activated)

recombinant DNA derived human blood coagulation factor VIIa (two protein chains) analogue, produced in CHO cells (glycoform alfa): [10-L-glutamine(P>Q),32-L-glutamic acid(K>E),34-L-glutamic acid(A>E),36-L-glutamic acid(R>E),106-L-asparagine(T>N), 253-L-asparagine(V>N)]activated human coagulation factor VII (proconvertine, SPCA)

oreptacog alfa (activé)

analogue du facteur de coagulation sanguine VIIa (deux chaînes protéiques) humain, produit par des cellules ovariennes de hamster chinois (CHO) à partir d'ADN recombinant (glycoforme alfa) : [10-L-glutamine(P>Q),32-L-acide glutamique(K>E),34-L-acide glutamique(A>E),36-L-acide glutamique(R>E), 106-L-asparagine(T>N),253-L-asparagine(V>N)]facteur de coagulation VII humain activé (proconvertine, SPCA)

oreptacog alfa (activado)

análogo del factor VIIa de coagulación (dos cadenas proteicas) humano, producido por células ováricas de hamster chino (CHO) a partir de ADN recombinante (glicoforma alfa) : [10-L-glutamina(P>Q),32-L-ácido glutámico(K>E),34-L-ácido glutámico (A>E),36-L-ácido glutámico(R>E), 106-L-asparagina(T>N),253-L-asparagina(V>N)]factor de coagulación VII humano activado (proconvertina, SPCA)

Light chain / Chaîne légère / Cadedena ligera

```
ANAFLEELRQ GSLERECKEE QCSFEEAREI FEDEEETKLF WISYSDGDQC 50
ASSPCQNGGS CKDQLQSYIC FCLPAFEGRN CETHKDDQLI CVNENGGCEQ 100
YCSDHNGTKR SCRCHEGYSL LADGVSCTPT VEYPCGKIPI LEKRNASKPQ 150
GR                                                    152
```

Heavy chain / Chaîne lourde / Cadena pesada

```
   IVGGKVCP KGECPWQVLL LVNGAQLCGG TLINTIWVVS AAHCFDKIKN 200
WRNLIAVLGE HDLSEHDGDE QSRRVAQVII PSTYVPGTTN HDIALLRLHQ 250
PVNLTDHVVP LCLPERTFSE RTLAFVRFSL VSGWGQLLDR GATALELMVL 300
NVPRLMTQDC LQQSRKVGDS PNITEYMFCA GYSDGSKDSC KGDSGGPHAT 350
HYRGTWYLTG IVSWGQGCAT VGHFGVYTRV SQYIEWLQKL MRSEPRPGVL 400
LRAPFP                                                406
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

17-22 50-61 55-70 72-81 91-102 98-112
114-127 135-262 159-164 178-194 310-329 340-368

Modified residues / Résidus modifiés / Restos modificados

E
6-7-14-16-19-20-25-26-29-32-34-35-36
4-carboxyGlu



Glycosylation sites (**S** or **N**) / Sites de glycosylation (**S** ou **N**) / Posiciones de glicosilación (**S** o **N**)

Ser-52 Ser-60 Asn-106 Asn-145 Asn-253 Asn-322

paclitaxelum trevatidum

paclitaxel trevatide

short modified fragment of human amyloid beta A4 protein covalently linked to three molecules of paclitaxel through succinyl linkers: $N^{2.1}$,$N^{6.10}$, $N^{6.15}$-tris{4-[(1*S*,2*R*)-1-benzamido-3-{[(2*S*,5*R*,7*S*,10*R*,13*S*)-10,12-bis(acetyloxy)-2-benzoyl-1,7-dihydroxy-9-oxo-5,20-epoxytax-11-en-13-yl]oxy}-3-oxo-1-phenylpropan-2-yl)oxy]-4-oxobutanoyl} ([318-L-threonine(P>$\underline{T}^{1}$),324-L-serine(C>S^{7}),325-L-arginine(G>R^{8}),327-L-lysine(N>$\underline{K}^{10}$),332-L-lysine(N>$\underline{K}^{15}$)] human amyloid beta A4 protein precursor-(318-336)-peptide)

paclitaxel trévatide

fragment court et modifié de la protéine bêta A4 amyloïde humaine lié de façon covalente à trois molécules de paclitaxel par autant de succinyles : $N^{2.1}$,$N^{6.10}$, $N^{6.15}$-tris{4-[(1*S*,2*R*)-1-benzamido-3-{[(2*S*,5*R*,7*S*,10*R*,13*S*)-10,12-bis(acétyloxy)-2-benzoyl-1,7-dihydroxy-9-oxo-5,20-époxytax-11-en-13-yl]oxy}-3-oxo-1-phénylpropan-2-yl)oxy]-4-oxobutanoyl} ([318-L-thréonine(P>$\underline{T}^{1}$),324-L-sérine(C>S^{7}),325-L-arginine(G>R^{8}),327-L-lysine(N>$\underline{K}^{10}$),332-L-lysine(N>$\underline{K}^{15}$)] précurseur de la protéine amyloïde bêta A4 humaine-(318-336)-peptide)

paclitaxel trevatida

fragmento corto y modificado de la proteína beta A4 amiloide humana unido covalentemente a tres moléculas de paclitaxel mediante succinilos :
N$^{2.1}$,*N*$^{6.10}$, *N*$^{6.15}$-tris{4-[(1*S*,2*R*)-1-benzamido-3-{[(2*S*,5*R*,7*S*,10*R*,13*S*)-10,12-bis(acetiloxi)-2-benzoil-1,7-dihidroxi-9-oxo-5,20-epoxitax-11-en-13-il]oxi}-3-oxo-1-fenilpropan-2-il)oxi]-4-oxobutanoil} ([318-L-treonina(P>T^{1}),324-L-serina(C>S^{7}),325-L-arginina(G>R^{8}),327-L-lisina(N>K^{10}),332-L-lisina(N>K^{15})] precursor de la proteína amiloide beta A4 humana-(318-336)-péptido
$C_{257}H_{308}N_{32}O_{79}$

Peptide / Peptide / Péptido
TFFYGGSRGK RNNFKTEEY 19

Modified residues / Résidus modifiés / Restos modificados



palbociclibum

palbociclib

6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-*d*]pyrimidin-7(8*H*)-one

palbociclib

6-acétyl-8-cyclopentyl-5-méthyl-2-{[5-(pipérazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-*d*]pyrimidin-7(8*H*)-one

palbociclib

6-acetil-8-ciclopentil-5-metil-2-{[5-(piperazin-1-il)piridin-2-il]amino}pirido[2,3-*d*]pirimidin-7(8*H*)-ona

$C_{24}H_{29}N_7O_2$



panulisibum

panulisib

2-(5-{(2*EZ*)-8-[6-amino-5-(trifluoromethyl)pyridin-3-yl]-2-(cyanoimino)-3-methyl-2,3-dihydro-1*H*-imidazo[4,5-*c*]quinolin-1-yl}pyridin-2-yl)-2-methylpropanenitrile

panulisib

2-(5-{(2*EZ*)-8-[6-amino-5-(trifluorométhyl)pyridin-3-yl]-2-(cyanoimino)-3-méthyl-2,3-dihydro-1*H*-imidazo[4,5-*c*]quinoléin-1-yl}pyridin-2-yl)-2-methylpropanenitrile

panulisib

2-(5-{(2*EZ*)-8-[6-amino-5-(trifluorometil)pyridin-3-il]-2-(cianoimino)-3-metil-2,3-dihidro-1*H*-imidazo[4,5-*c*]quinolin-1-il}piridin-2-il)-2-metilpropanonitrilo

$C_{27}H_{20}F_3N_9$



patisiranum

patisiran — small interfering RNA (siRNA);
RNA duplex of guanylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-adenylyl-(3'→5')-adenylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-adenylyl-(3'→5')-adenylyl-(3'→5')-guanylyl-(3'→5')-adenylyl-(3'→5')-guanylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-adenylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-adenylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-thymidylyl-(3'→5')-thymidine with thymidylyl-(5'→3')-thymidylyl-(5'→3')-cytidylyl-(5'→3')-adenylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-uridylyl-(5'→3')-guanylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-uridylyl-(5'→3')-cytidylyl-(5'→3')-uridylyl-(5'→3')-cytidylyl-(5'→3')-adenylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-adenylyl-(5'→3')-guanylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-adenosine

patisiran — petit ARN interférant (siRNA);
duplex ARN du brin guanylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-adénylyl-(3'→5')-adénylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-adénylyl-(3'→5')-adénylyl-(3'→5')-guanylyl-(3'→5')-adénylyl-(3'→5')-guanylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-adénylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-adénylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-thymidylyl-(3'→5')-thymidine avec le brin anti-sens thymidylyl-(5'→3')-thymidylyl-(5'→3')-cytidylyl-(5'→3')-adénylyl-(5'→3')-2'-*O*-méthyluridylyl-(5'→3')-uridylyl-(5'→3')-guanylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-uridylyl-(5'→3')-cytidylyl-(5'→3')-uridylyl-(5'→3')-cytidylyl-(5'→3')-adénylyl-(5'→3')-2'-*O*-méthyluridylyl-(5'→3')-adénylyl-(5'→3')-adénylyl-(5'→3')-guanylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-adénosine

patisirán — ARN interferente pequeño (siRNA);
ARN dúplex de la cadena guanilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-adenilil-(3'→5')-adenilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-adenilil-(3'→5')-adenilil-(3'→5')-guanilil-(3'→5')-adenilil-(3'→5')-guanilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-adenilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-adenilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-timidilil-(3'→5')-timidina con la cadena antisentido timidilil-(5'→3')-timidilil-(5'→3')-citidilil-(5'→3')-adenilil-(5'→3')-2'-*O*-metiluridilil-(5'→3')-uridilil-(5'→3')-guanilil-(5'→3')-guanilil-(5'→3')-uridilil-(5'→3')-uridilil-(5'→3')-citidilil-(5'→3')-uridilil-(5'→3')-citidilil-(5'→3')-adenilil-(5'→3')-2'-*O*-metiluridilil-(5'→3')-adenilil-(5'→3')-adenilil-(5'→3')-guanilil-(5'→3')-guanilil-(5'→3')-uridilil-(5'→3')-adenosina

$C_{412}H_{480}N_{148}O_{290}P_{40}$

(3'-5')G-U-A-A-C-C-A-A-G-A-G-U-A-U-U-C-C-A-U-dT-dT
(5'-3')dT-dT-C-A-U-U-G-G-U-U-C-U-C-A-U-A-A-G-G-U-A

Modified nucleosides (C and U) / Nucléosides modifiés (C et U) / Nucleósidos modificados (C y U)



pegbovigrastimum #

pegbovigrastim

recombinant DNA derived bovine granulocyte colony-stimulating factor (G-CSF) analogue, produced in *Escherichia coli* (nonglycosylated), covalently bonded to methoxy polyethylene glycol:
L-methionyl-[133-{4-(1-{[2-({[ω-methoxypoly(oxyethylene)]carbonyl}amino)ethoxy]imino}ethyl)-L-phenylalanine(T>F)}]bovine granulocyte colony-stimulating factor (G-CSF)

pegbovigrastim

analogue du facteur de stimulation de colonies de granulocytes bovin, produit par *Escherichia coli* à partir d'ADN recombinant (non glycosylé), auquel est liée de façon covalente une chaîne méthoxypolyéthylèneglycol :
L-méthionyl-[133-{4-(1-{[2-({[ω-méthoxypoly(oxyéthylène)]carbonyl}amino)éthoxy]imino}éthyl)-L-phénylalanine(T>F)}]facteur de stimulation des colonies de granulocytes (G-CSF) bovin

pegbovigrastim

análogo del factor bovino estimulante de colonias de granulocitos, producido por *Escherichia coli* a partir de ADN recombinante (no glicosilado), al cual se une covalentemente una cadena metoxipolietilenglicol :
L-metionil-[133-{4-(1-{[2-({[ω-metoxipoli(oxietileno)]carbonil}amino)etoxi]imino}etil)-L-fenilalanina(T>F)}]factor estimulante de colonias de granulocitos (G-CSF) bovino

$C_{859}H_{1370}N_{236}O_{248}S_9 \cdot [C_2H_4O]_n$

Sequence / Séquence / Secuencia

```
                                                          M
TPLGPARSLP QSFLLKCLEQ VRKIQADGAE LQERLCAAHK LCHPEELMLL 50
RHSLGIPQAP LSSCSSQSLQ LTSCLNQLHG GLFLYQGLLQ ALAGISPELA 100
PTLDTLQLDV TDFATNIWLQ MEDLGAAPAV QPFQGAMPTF TSAFQRRAGG 150
VLVASQLHRF LELAYRGLRY LAEP                              174
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
36-42 64-74

Modified residue / Résidu modifié / Resto modificado



F 133
4-(methoxyPEGcarbonylaminoethoxyiminoethyl)Phe

pegteograstimum #

pegteograstim

recombinant DNA derived human granulocyte colony-stimulating factor (G-CSF) analogue, produced in *Escherichia coli* (nonglycosylated), covalently bonded to methoxy polyethylene glycol:
endo-139a-*S*-{(3*RS*)-1-[3-({3-[ω-methoxypoly(oxyethylene)]propyl}amino)-3-oxopropyl]-2,5-dioxopyrrolidin-3-yl}-L-cysteine (->C^{137})-des-(37-39)-[1-L-methionine(A>M),18-L-serine(C>S)]human granulocyte colony stimulating factor (G-CSF, pluripoietin)

pegtéograstim

analogue du facteur humain de stimulation de colonies de granulocytes, produit par *Escherichia coli* à partir d'ADN recombinant (non glycosylé), auquel est lié de façon covalente une chaîne méthoxypolyéthylèneglycol :
endo-139a-*S*-{(3*RS*)-1-[3-({3-[ω-méthoxypoly(oxyéthylène)]propyl}amino)-3-oxopropyl]-2,5-dioxopyrrolidin-3-yl}-L-cystéine(->C^{137})-dès-(37-39)-[1-L-méthionine(A>M),18-L-sérine(C>S)]facteur humain de stimulation de colonies de granulocytes (G-CSF, pluripoïétine)

pegteograstim

análogo del factor humano estimulante de colonias de granulocitos, producido por *Escherichia coli* a partir de ADN recombinante (no glicosilado), al que se une covalentemente una cadena metoxipolietilenglicol:
endo-139a-*S*-{(3*RS*)-1-[3-({3-[ω-metoxipoli(oxietileno)]propil}amino)-3-oxopropil]-2,5-dioxopirrolidin-3-il}-L-cisteina(->C^{137})-des-(37-39)-[1-L-metionina(A>M),18-L-serina(C>S)]factor humano estimulante de colonias de granulocitos (G-CSF, pluripoyetina)

$C_{859}H_{1360}N_{226}O_{249}S_9$. $[C_2H_4O]_n$

Sequence / Séquence / Secuencia

```
MTPLGPASSL PQSFLLKSLE QVRKIQGDGA ALQEKLCATY KLCHPEELVL 50
LGHSLGIPWA PLSSCPSQAL QLAGCLSQLH SGLFLYQGLL QALEGISPEL 100
GPTLDTLQLD VADFATTIWQ QMEELGMAPA LQPTQGCAMP AFASAFQRRA 150
GGVLVASHLQ SFLEVSYRVL RHLAQP                         176
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
37-43 65-75

Modified residue / Résidu modifié / Resto modificado



pevonedistatum

pevonedistat

[(1*S*,2*S*,4*R*)-4-(4-{[(1*S*)-2,3-dihydro-1*H*-inden-1-yl]amino}-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl)-2-hydroxycyclopentyl]methyl sulfamate

pévonédistat

sulfamate de [(1*S*,2*S*,4*R*)-4-(4-{[(1*S*)-2,3-dihydro-1*H*-indén-1-yl]amino}-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl)-2-hydroxycyclopentyl]méthyle

pevonedistat

sulfamato de (1*S*,2*S*,4*R*)-4-(4-{[(1*S*)-2,3-dihidro-1*H*-inden-1-il]amino}-7*H*-pirrolo[2,3-*d*]pirimidin-7-il)-2-hidroxiciclopentil]metilo

$C_{21}H_{25}N_5O_4S$



ralimetinibum

ralimetinib	5-[2-*tert*-butyl-5-(4-fluorophenyl)-1*H*-imidazol-4-yl]-3-(2,2-dimethylpropyl)-3*H*-imidazo[4,5-*b*]pyridin-2-amine
ralimétinib	5-[2-*tert*-butyl-5-(4-fluorophényl)-1*H*-imidazol-4-yl]-3-(2,2-diméthylpropyl)-3*H*-imidazo[4,5-*b*]pyridin-2-amine
ralimetinib	5-[2-*terc*-butil-5-(4-fluorofenil)-1*H*-imidazol-4-il]-3-(2,2-dimetilpropil)-3*H*-imidazo[4,5-*b*]piridin-2-amina

$C_{24}H_{29}FN_6$



remeglurantum

remeglurant	(6-bromopyrazolo[1,5-*a*]pyrimidin-2-yl)[(1*R*)-1-methyl-3,4-dihydroisoquinolin-2(1*H*)-yl]methanone
réméglurant	(6-bromopyrazolo[1,5-*a*]pyrimidin-2-yl)[(1*R*)-1-méthyl-3,4-dihydroisoquinoléin-2(1*H*)-yl]méthanone
remeglurant	(6-bromopirazolo[1,5-*a*]pirimidin-2-il)[(1*R*)-1-metil-3,4-dihidroisoquinolin-2(1*H*)-il]metanona

$C_{17}H_{15}BrN_4O$



ricolinostatum

ricolinostat	2-(diphenylamino)-*N*-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-5-carboxamide
ricolinostat	2-(diphénylamino)-*N*-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-5-carboxamide
ricolinostat	2-(difenilamino)-*N*-[7-(hidroxiamino)-7-oxoheptil]pirimidina-5-carboxamida

$C_{24}H_{27}N_5O_3$



rimegepantum

rimegepant	(5*S*,6*S*,9*R*)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5*H*-cyclohepta[*b*]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1*H*-imidazo[4,5-*b*]pyridin-1-yl)piperidine-1-carboxylate
rimégépant	4-(2-oxo-2,3-dihydro-1*H*-imidazo[4,5-*b*]pyridin-1-yl)pipéridine-1-carboxylate de (5*S*,6*S*,9*R*)-5-amino-6-(2,3-difluorophényl)-6,7,8,9-tétrahydro-5*H*-cyclohepta[*b*]pyridin-9-yle
rimegepant	4-(2-oxo-2,3-dihidro-1*H*-imidazo[4,5-*b*]piridin-1-il)piperidina-1-carboxilato de (5*S*,6*S*,9*R*)-5-amino-6-(2,3-difluorofenil)-6,7,8,9-tetrahidro-5*H*-ciclohepta[*b*]piridin-9-ilo

$C_{28}H_{28}F_2N_6O_3$



ripasudilum

ripasudil	4-fluoro-5-{[(2*S*)-2-methyl-1,4-diazepan-1-yl]sulfonyl}isoquinoline
ripasudil	4-fluoro-5-{[(2*S*)-2-méthyl-1,4-diazépan-1-yl]sulfonyl}isoquinoléine
ripasudil	4-fluoro-5-{[(2*S*)-2-metil-1,4-diazepan-1-il]sulfonil}isoquinolina

$C_{15}H_{18}FN_3O_2S$



riviciclibum

riviciclib	2-(2-chlorophenyl)-5,7-dihydroxy-8-[(2*R*,3*S*)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]-4*H*-1-benzopyran-4-one
riviciclib	2-(2-chlorophényl)-5,7-dihydroxy-8-[(2*R*,3*S*)-2-(hydroxyméthyl)-1-méthylpyrrolidin-3-yl]-4*H*-1-benzopyran-4-one
riviciclib	2-(2-clorofenil)-5,7-dihidroxi-8-[(2*R*,3*S*)-2-(hidroximetil)-1-metilpirrolidin-3-il]-4*H*-1-benzopiran-4-ona

$C_{21}H_{20}ClNO_5$



rivipanselum

rivipansel	(2*S*)-3-cyclohexyl-2-([(1*R*,2*R*,3*S*,5*R*)-2-[(6-deoxy-α-L-galactopyranosyl)oxy]-3-(2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-carboxamido)-5-{13-[(3,6,8-trisulfonatonaphthalene-1-yl)amino]-6,13-dioxo-2,5-diaza-8,11-dioxatridecanoyl}cyclohexyl]{2-*O*-benzoyl-β-D-galactopyranosid-3-*O*-yl})propanoic acid
rivipansel	acide (2*S*)-3-cyclohexyl-2-([(1*R*,2*R*,3*S*,5*R*)-2-[(6-déoxy-α-L-galactopyranosyl)oxy]-3-(2,6-dioxo-1,2,3,6-tétrahydropyrimidin-4-carboxamido)-5-{13-[(3,6,8-trisulfonatonaphtalèn-1-yl)amino]-6,13-dioxo-2,5-diaza-8,11-dioxatridécanoyl}cyclohexyl]{2-*O*-benzoyl-β-D-galactopyranosid-3-*O*-yl})propanoïque
rivipansel	ácido (2*S*)-3-ciclohexil-2-([(1*R*,2*R*,3*S*,5*R*)-2-[(6-desoxi-α-L-galactopiranosil)oxi]-3-(2,6-dioxo-1,2,3,6-tetrahidropirimidin-4-carboxamido)-5-{13-[(3,6,8-trisulfonatonaftalen-1-il)amino]-6,13-dioxo-2,5-diaza-8,11-dioxatridecanoil}ciclohexil]{2-*O*-benzoil-β-D-galactopiranosid-3-*O*-il})propanoico

$C_{58}H_{74}N_6O_{31}S_3$



roniciclibum

roniciclib — cyclopropyl(4-{[4-{[(2*R*,3*R*)-3-hydroxybutan-2-yl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)imino-λ^5-sulfanone

roniciclib — cyclopropyl(4-{[4-{[(2*R*,3*R*)-3-hydroxybutan-2-yl]oxy}-5-(trifluorométhyl)pyrimidin-2-yl]amino}phényl)imino-λ^5-sulfanone

roniciclib — ciclopropil(4-{[4-{[(2*R*,3*R*)-3-hidroxibutan-2-il]oxi}-5-(trifluorometil)pirimidin-2-il]amino}fenil)imino-λ^5-sulfanona

$C_{18}H_{21}F_3N_4O_3S$



ropeginterferonum alfa-2b #

ropeginterferon alfa-2b — recombinant DNA derived human interferon alfa-2b with an added pegylated proline at its *N*-terminal, produced in *Escherichia coli* (nonglycosylated): {1-[(3*RS*)-3,7-bis{[(ω-methoxypoly(oxyethylene)carbonyl]amino}heptyl]-L-prolyl}human interferon alpha-2B

ropéginterféron alfa-2b — interféron alfa-2b humain auquel une proline pégylée a été rajoutée du coté *N*-terminal, produit par *Escherichia coli* (non glycosylé) à partir d'ADN recombinant : {1-[(3*RS*)-3,7-bis{[(ω-méthoxypoly(oxyéthylène)carbonyl]amino}heptyl]-L-prolyl}interféron alpha-2B humain

ropeginterferon alfa-2b — interferón alfa-2b humano con una prolina pegilada unida al extremo *N*-terminal, producido por *Escherichia coli* (no glicosilado) a partir de ADN recombinante : {1-[(3*RS*)-3,7-bis{[(ω-metoxipoli(oxietilen)carbonil]amino}heptil]-L-prolil}interferón alfa-2B humano

$C_{876}H_{1376}N_{232}O_{260}S_9[C_2H_4O]_{2n}$

Sequence / Séquence / Secuencia

```
                                                          P 0
CDLPQTHSLG SRRTLMLLAQ MRRISLFSCL KDRHDFGFPQ EEFGNQFQKA 50
ETIPVLHEMI QQIFNLFSTK DSSAAWDETL LDKFYTELYQ QLNDLEACVI 100
QGVGVTETPL MKEDSILAVR KYFQRITLYL KEKKYSPCAW EVVRAEIMRS 150
FSLSTNLQES LRSKE                                        165
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
1-98 29-138

Modified residue / Résidu modifié / Resto modificado

P

1-[(mPEG)2link]Prolyl



sacubitrilum

sacubitril	4-{[(2*S*,4*R*)-1-([1,1'-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl]amino}-4-oxobutanoic acid
sacubitril	acide 4-{[(2*S*,4*R*)-1-([1,1'-biphényl]-4-yl)-5-éthoxy-4-méthyl-5-oxopentan-2-yl]amino}-4-oxobutanoïque
sacubitrilo	ácido 4-{[(2*S*,4*R*)-1-([1,1'-bifenil]-4-il)-5-etoxi-4-metil-5-oxopentan-2-il]amino}-4-oxobutanoico

$C_{24}H_{29}NO_5$



sarecyclinum

sarecycline	(4*S*,4a*S*,5a*R*,12a*S*)-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-7-{[methoxy(methyl)amino]methyl}-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
sarécycline	(4*S*,4a*S*,5a*R*,12a*S*)-4-(diméthylamino)-3,10,12,12a-tétrahydroxy-7-{[méthoxy(méthyl)amino]méthyl}-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotétracène-2-carboxamide
sareciclina	(4*S*,4a*S*,5a*R*,12a*S*)-4-(dimetilamino)-3,10,12,12a-tetrahidroxi-7-{[metoxi(metil)amino]metil}-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahidrotetraceno-2-carboxamida

$C_{24}H_{29}N_3O_8$



sarsageninum

sarsagenin	(25*S*)-5β-spirostan-3β-ol
sarsagénine	(25*S*)-5β-spirostan-3β-ol
sarsagenina	(25*S*)-5β-espirostan-3β-ol

$C_{27}H_{44}O_3$



sisapronilum

sisapronil	5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(1*RS*)-2,2-difluoro-1-(trifluoromethyl)cyclopropyl]-1*H*-pyrazole-3-carbonitrile
sisapronil	5-amino-1-[2,6-dichloro-4-(trifluorométhyl)phényl]-4-[(1*RS*)-2,2-difluoro-1-(trifluorométhyl)cyclopropyl]-1*H*-pyrazole-3-carbonitrile
sisapronilo	5-amino-1-[2,6-dicloro-4-(trifluorometil)fenil]-4-[(1*RS*)-2,2-difluoro-1-(trifluorometil)ciclopropil]-1*H*-pirazol-3-carbonitrilo

$C_{15}H_6Cl_2F_8N_4$



and enantiomer
et énantiomère
y enantiómero

smilageninum

smilagenin	(25*R*)-5β-spirostan-3β-ol
smilagénine	(25*R*)-5β-spirostan-3β-ol
esmilagenina	(25*R*)-5β-espirostan-3β-ol

$C_{27}H_{44}O_3$



tanurmotidum

tanurmotide	human lymphocyte antigen 6K-(101-111)-peptide
tanurmotide	antigène 6K lymphocytaire humain-(101-111)-peptide
tanurmotida	antígeno 6K linfocitario humano-(101-111)-péptido

$C_{51}H_{80}N_{14}O_{15}S$

Sequence / Séquence / Secuencia
RYCNLEGPPI 10

tarextumabum #

tarextumab	immunoglobulin G2-kappa, anti-[*Homo sapiens* NOTCH2 and NOTCH3], *Homo sapiens* monoclonal antibody; gamma2 heavy chain (1-441) [*Homo sapiens* VH (IGHV3-66*01 (93.90%) -(IGHD)-IGHJ6*01 T123>L (110)) [8.8.8] (1-115) - IGHG2*01 (CH1 (116-213), hinge (214-225), CH2 (226-334), CH3 (335-439), CHS (440-441)) (116-441)], (129-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*02 (94.40%) -IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; dimer (217-217'':218-218'':221-221'':224-224'')-tetrakisdisulfide
tarextumab	immunoglobuline G2-kappa, anti-[*Homo sapiens* NOTCH2 et NOTCH3], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma2 (1-441) [*Homo sapiens* (IGHV3-66*01 (93.90%) -(IGHD)-IGHJ6*01 T123>L (110)) [8.8.8] (1-115) - IGHG2*01 (CH1 (116-213), charnière (214-225), CH2 (226-334), CH3 (335-439), CHS (440-441)) (116-441)], (129-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*02 (94.40%) -IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; dimère (217-217'':218-218'':221-221'':224-224'')-tétrakisdisulfure
tarextumab	inmunoglobulina G2-kappa, anti-[NOTCH2 y NOTCH3 de *Homo sapiens*], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma2 (1-441) [*Homo sapiens* (IGHV3-66*01 (93.90%) -(IGHD)-IGHJ6*01 T123>L (110)) [8.8.8] (1-115) - IGHG2*01 (CH1 (116-213), bisagra (214-225), CH2 (226-334), CH3 (335-439), CHS (440-441)) (116-441)], (129-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*02 (94.40%) -IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; dímero (217-217'':218-218'':221-221'':224-224'')-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS SSGMSWVRQA PGKGLEWVSV  50
IASSGSNTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARSI 100
FYTTWGQGTL VTVSSASTKG PSVFPLAPCS RSTSESTAAL GCLVKDYFPE 150
PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSN FGTQTYTCNV 200
DHKPSNTKVD KTVERKCCVE CPPCPAPPVA GPSVFLFPPK PKDTLMISRT 250
PEVTCVVVDV SHEDPEVQFN WYVDGVEVHN AKTKPREEQF NSTFRVVSVL 300
TVVHQDWLNG KEYKCKVSNK GLPAPIEKTI SKTKGQPREP QVYTLPPSRE 350
EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP MLDSDGSFFL 400
YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K          441
```

Light chain / Chaîne légère / Cadena ligera

```
DIVLTQSPAT LSLSPGERAT LSCRASQSVR SNYLAWYQQK PGQAPRLLIY  50
GASSRATGVP ARFSGSGSGT DFTLTISSLE PEDFAVYYCQ QYSNFPITFG 100
QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC                                       215
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	142-198	255-315	361-419
	22"-96"	142"-198"	255"-315"	361"-419"
Intra-L (C23-C104)	23'-89'	135'-195'		
	23'"-89'"	135'"-195'"		
Inter-H-L (CH1 10-CL 126)	129-215'	129"-215'"		
Inter-H-H (h 4, h 5, h 8, h 11)	217-217"	218-218"	221-221"	224-224"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
291, 291"

taselisibum

taselisib — 2-methyl-2-(4-{2-[3-methyl-1-(propan-2-yl)-1*H*-1,2,4-triazol-5-yl]-5,6-dihydroimidazo[1,2-*d*][1,4]benzoxazepin-9-yl}-1*H*-pyrazol-1-yl)propanamide

tasélisib — 2-méthyl-2-(4-{2-[3-méthyl-1-(propan-2-yl)-1*H*-1,2,4-triazol-5-yl]-5,6-dihydroimidazo[1,2-*d*][1,4]benzoxazépin-9-yl}-1*H*-pyrazol-1-yl)propanamide

taselisib — 2-metil-2-(4-{2-[3-metil-1-(propan-2-il)-1*H*-1,2,4-triazol-5-yl]-5,6-dihidroimidazo[1,2-*d*][1,4]benzoxazepin-9-il}-1*H*-pirazol-1-il)propanamida

$C_{24}H_{28}N_8O_2$



technetii (^{99m}Tc) trofolastati chloridum

technetium (^{99m}Tc) trofolastat chloride — (*OC*-6-33)-tricarbonyl{(2*S*)-2-[({(1*S*)-1-carboxy-4-{[(1*S*)-1-carboxy-5-(bis{[1-(2-{[bis(carboxymethyl)]amino}-2-oxoethyl)-1*H*-imidazol-2-yl-κ*N*^{3}]methyl}amino-κ*N*)pentyl]amino}-4-oxobutyl]carbamoyl}amino)pentanedioic acid}(^{99m}Tc)technetium chloride

chlorure de technétium (^{99m}Tc) trofolastat — chlorure de (^{99m}Tc)technétium acide (*OC*-6-33)-tricarbonyl{(2*S*)-2-[({(1*S*)-1-carboxy-4-{[(1*S*)-1-carboxy-5-(bis{[1-(2-{[bis(carboxyméthyl)]amino}-2-oxoéthyl)-1*H*-imidazol-2-yl-κ*N*^{3}]méthyl}amino-κ*N*)pentyl]amino}-4-oxobutyl]carbamoyl}amino)pentanedioïque}

cloruro de tecnecio (^{99m}Tc) trofolastat — cloruro de ácido (*OC*-6-33)-tricarbonil{(2*S*)-2-[({(1*S*)-1-carboxi-4-{[(1*S*)-1-carboxi-5-(bis{[1-(2-{[bis(carboximetil)]amino}-2-oxoetil)-1*H*-imidazol-2-il-κ*N*^{3}]metil}amino-κ*N*)pentil]amino}-4-oxobutil]carbamoil}amino)pentanedioico }(^{99m}Tc)tecnecio

$C_{40}H_{50}ClN_{10}O_{23}Tc$



topsalysinum #

topsalysin

recombinant DNA derived proaerolysin, pore-forming protein, from *Aeromonas hydrophila,* with the furin site substituted with a prostate specific antigen (PSA), fusion protein with 6 histidines, produced in *Escherichia coli* (nonglycosylated):
[427-L-histidine(K>H),428-L-serine(V>S),429-L-serine(R>S),430-L-lysine(R>K),431-L-leucine(A>L),432-L-glutamine(R>Q)]proaerolysin *Aeromonas hydrophila* fusion protein with hexa-L-histidine

topsalysine

proaérolysine, protéine formant des pores, d'*Aeromonas hydrophila* dont le site furine est substitué par un antigène prostatique spécifique, protéine de fusion avec 6 histidines, produit par *Escherichia coli* à partir d'ADN recombinant (non glycosylé) :
[427-L-histidine(K>H),428-L-sérine(V>S),429-L-sérine(R>S),430-L-lysine(R>K),431-L-leucine(A>L),432-L-glutamine(R>Q)]proaérolysine d'*Aeromonas hydrophila* protéine de fusion avec l'hexa-L-histidine

topsalisina

proaerolisina, proteína formadora de poros, d'*Aeromonas hydrophila* cuyo sitio furina está substituido por un antígeno prostático específico, proteína de fusión con 6 histidinas, producida por *Escherichia coli* a partir de ADN recombinante (no glicosilado) :
[427-L-histidina(K>H),428-L-serina(V>S),429-L-serina (R>S),430-L-lisina(R>K),431-L-leucina(A>L),432-L-glutamina(R>Q)]proaerolisina d'*Aeromonas hydrophila* proteina de fusión con hexa-L-histidina

Sequence / Séquence / Secuencia

```
AEPVYPDQLR LFSLGQGVCG DKYRPVNREE AQSVKSNIVG MMGQWQISGL 50
ANGWVIMGPG YNGEIKPGTA SNTWCYPTNP VTGEIPTLSA LDIPDGDEVD 100
VQWRLVHDSA NFIKPTSYLA HYLGYAWVGG NHSQYVGEDM DVTRDGDGWV 150
IRGNNDGGCD GYRCGDKTAI KVSNFAYNLD PDSFKHGDVT QSDRQLVKTV 200
VGWAVNDSDT PQSGYDVTLR YDTATNWSKT NTYGLSEKVT TKNKFKWPLV 250
GETELSIEIA ANQSWASQNG GSTTTSLSQS VRPTVPARSK IPVKIELYKA 300
DISYPYEFKA DVSYDLTLSG FLRWGGNAWY THPDNRPNWN HTFVIGPYKD 350
KASSIRYQWD KRYIPGEVKW WDWNWTIQQN GLSTMQNNLA RVLRPVRAGI 400
TGDFSAESQF AGNIEIGAPV PLAADSHSSK LQSVDGAGQG LRLEIPLDAQ 450
ELSGLGFNNV SLSVTPAANQ HHHHHH                          476
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
19-75 159-164

tosatoxumabum #

tosatoxumab

immunoglobulin G1-lambda2, anti-[*Staphylococcus aureus* alpha-toxin (alpha-hemolysin, alpha-HL, hly, hla)], *Homo sapiens* monoclonal antibody;gamma1 heavy chain (1-451) [*Homo sapiens* VH (IGHV5-51*01 (81.60%) -(IGHD)-IGHJ1*01 L123>M (116)) [8.8.14] (1-121) -IGHG1*01 (CH1 (122-219), hinge (220-234), CH2 (235-344), CH3 (345-449), CHS (450-451)) (122-451)], (224-216')-disulfide with lambda light chain (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-44*01 (93.90%) -IGLJ1*01) [8.3.12] (1'-111') -IGLC1*01 (112'-217')]; dimer (230-230":233-233")-bisdisulfide

tosatoxumab

immunoglobuline G1-lambda2, anti-[*Staphylococcus aureus* toxine alpha (hémolysine alpha, HL-alpha, hly, hla)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-451) [*Homo sapiens* VH (IGHV5-51*01 (81.60%) -(IGHD)-IGHJ1*01 L123>M (116)) [8.8.14] (1-121) -IGHG1*01 (CH1 (122-219), charnière (220-234), CH2 (235-344), CH3 (345-449), CHS (450-451)) (122-451)], (224-216')-disulfure avec la chaîne légère lambda (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-44*01 (93.90%) -IGLJ1*01) [8.3.12] (1'-111') -IGLC1*01 (112'-217')]; dimère (230-230":233-233")-bisdisulfure

tosatoxumab

inmunoglobulina G1-lambda2, anti-[toxina alfa de *Staphylococcus aureus* (hemolisina alfa, HL-alfa, hly, hla)], anticuerpo monoclonal de *Homo sapiens*;
gamma1 (1-451) [*Homo sapiens* VH (IGHV5-51*01 (81.60%) -(IGHD)-IGHJ1*01 L123>M (116)) [8.8.14] (1-121) -cadena pesada (224-216')-disulfuro con la cadena ligera lambda (1'-217') [*Homo sapiens* (IGLV1-44*01 (93.90%) -IGLJ1*01) [8.3.12] (1'-111') -IGLC1*01 (112'-217')]; dímero (230-230":233-233")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQMVQSGAE VKKPGEPLKI SCKGSGYKFG THWIGWVRQR PGKGLEWMGI  50
IHPADSETKY SPSFQGQVSF SADKSSNTAY LHWSTLRASD TAMYYCARRS 100
GSSSWYALDF WGQGTMVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKRVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450
K                                                       451
```

Light chain / Chaîne légère / Cadena ligera

```
QSVLTQSPSA SGTPGQRVTI SCSGGSSNIG SNTVNWYQQF PGAAPKLLIY  50
TNNQRPSGVP DRFSGSKSGT SASLAISGLQ SEDEADYYCA TWDDSLNGLY 100
VFGTGTKVTV LGQPKANPTV TLFPPSSEEL QANKATLVCL ISDFYPGAVT 150
VAWKADGSPV KAGVETTKPS KQSNNKYAAS SYLSLTPEQW KSHRSYSCQV 200
THEGSTVEKT VAPTECS                                     217
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	148-204	265-325	371-429
	22"-96"	148"-204"	265"-325"	371"-429"
Intra-L (C23-C104)	22'-89'	139'-198'		
	22'"-89'"	139'"-198'"		
Inter-H-L (h 5-CL 126)	224-216'	224"-216'"		
Inter-H-H (h 11, h 14)	230-230"	233-233"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
301, 301"

tovetumabum #

tovetumab

immunoglobulin G2-kappa, anti-[*Homo sapiens* PDGFRA (platelet-derived growth factor receptor alpha subunit, PDGFR2, CD140a)], *Homo sapiens* monoclonal antibody;
gamma2 heavy chain (1-446) [*Homo sapiens* VH (IGHV3-11*01 (98.00%) -(IGHD)-IGHJ6*01) [8.8.13] (1-120) -IGHG2*01 (CH1 (121-218), hinge (219-230), CH2 (231-339), CH3 (340-444), CHS (445-446)) (121-446)], (134-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (89.50%) -IGKJ5*01 I126>M (107)) [6.3.10] (1'-108') -IGKC*01 (109'-215')]; dimer (222-222":223-223":226-226":229-229")-tetrakisdisulfide

tovétumab

immunoglobuline G2-kappa, anti-[*Homo sapiens* PDGFRA (sous-unité alpha du récepteur du facteur de croissance dérivé des plaquettes, PDGFR2, CD140a)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma2 (1-446) [*Homo sapiens* VH (IGHV3-11*01 (98.00%) -(IGHD)-IGHJ6*01) [8.8.13] (1-120) -IGHG2*01 (CH1 (121-218), charnière (219-230), CH2 (231-339), CH3 (340-444), CHS (445-446)) (121-446)], (134-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (89.50%) -IGKJ5*01 I126>M (107)) [6.3.10] (1'-108') -IGKC*01 (109'-215')]; dimère (222-222":223-223":226-226":229-229")-tétrakisdisulfure

tovetumab

inmunoglobulina G2-kappa, anti-[PDGFRA *de Homo sapiens* (subunidad alfa del receptor del factor de crecimiento derivado de las plaquetas, PDGFR2, CD140a)], anticuerpo monoclonal de *Homo sapiens;*
cadena pesada gamma2 (1-446) [*Homo sapiens* VH (IGHV3-11*01 (98.00%) -(IGHD)-IGHJ6*01) [8.8.13] (1-120) -IGHG2*01 (CH1 (121-218), bisagra (219-230), CH2 (231-339), CH3 (340-444), CHS (445-446)) (121-446)], (134-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (89.50%) -IGKJ5*01 I126>M (107)) [6.3.10] (1'-108') -IGKC*01 (109'-215')]; dímero (222-222'':223-223'':226-226'':229-229'')-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVESGGG LVKPGGSLRL SCAASGFTFS DYYMNWIRQA PGKGLEWVSY  50
ISSSGSIIYY ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCAREG 100
RIAARGMDVW GQGTTVTVSS ASTKGPSVFP LAPCSRSTSE STAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSNFGTQT 200
YTCNVDHKPS NTKVDKTVER KCCVECPPCP APPVAGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSHEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTFR 300
VVSVLTVVHQ DWLNGKEYKC KVSNKGLPAP IEKTISKTKG QPREPQVYTL 350
PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPMLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK     446
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVS ITCRPSQSFS RYINWYQQKP GKAPKLLIHA  50
ASSLVGGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ TYSNPPITFG 100
QGTRLEMKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC                                       215
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 147-203 260-320 366-424
22''-96'' 147''-203'' 260''-320'' 366''-424''
Intra-L (C23-C104) 23'-88' 135'-195'
23'''-88''' 135'''-195'''
Inter-H-L (CH1 10-CL 126) 134-215' 134''-215'''
Inter-H-H (h 4, h 5, h 8, h 11) 222-222'' 223-223'' 226-226'' 229-229''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
296, 296''

ubrogepantum

ubrogepant

(3'*S*)-*N*-[(3*S*,5*S*,6*R*)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[*b*]pyridine-6,3'-pyrrolo[2,3-*b*]pyridine]-3-carboxamide

ubrogépant

(3'*S*)-*N*-[(3*S*,5*S*,6*R*)-6-méthyl-2-oxo-5-phényl-1-(2,2,2-trifluoroéthyl)pipéridin-3-yl]-2'-oxo-1',2',5,7-tétrahydrospiro[cyclopenta[*b*]pyridine-6,3'-pyrrolo[2,3-*b*]pyridine]-3-carboxamide

ubrogepant

(3'*S*)-*N*-[(3*S*,5*S*,6*R*)-6-metil-2-oxo-5-fenil-1-(2,2,2-trifluoroetil)piperidin-3-il]-2'-oxo-1',2',5,7-tetrahidrospiro[ciclopenta[*b*]piridina-6,3'-pirrolo[2,3-*b*]piridina]-3-carboxamida

$C_{29}H_{26}F_3N_5O_3$



valbenazinum

valbenazine — (2*R*,3*R*,11b*R*)-9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2*H*-pyrido[2,1-*a*]isoquinolin-2-yl L-valinate

valbénazine — L-valinate de (2*R*,3*R*,11b*R*)-9,10-diméthoxy-3-(2-méthylpropyl)-1,3,4,6,7,11b-hexahydro-2*H*-pyrido[2,1-*a*]isoquinoléin-2-yle

valbenazina — L-valinato de (2*R*,3*R*,11b*R*)-9,10-dimetoxi-3-(2-metilpropil)-1,3,4,6,7,11b-hexahidro-2*H*-pirido[2,1-*a*]isoquinolein-2-ylo

$C_{24}H_{38}N_2O_4$



vantictumabum #

vantictumab — immunoglobulin G2-lambda, anti-[*Homo sapiens* frizzled family receptor (FZD), including FZD1, FZD2, FZD5, FZD7 and FZD8)], *Homo sapiens* monoclonal antibody;
gamma2 heavy chain (1-443) [*Homo sapiens* VH (IGHV3-23*04 (90.80%) -(IGHD)-IGHJ6*01 T123>L (113)) [8.8.11] (1-118) - IGHG2*01 (CH1 (119-216), hinge (217-228), CH2 (229-337), CH3 (338-441), CHS (442-443)) (119-443)], (132-212')-disulfide with lambda light chain (1'-213') [*Homo sapiens* V-LAMBDA (IGLV3-25*02 (81.60%) -IGLJ2*01) [6.3.10] (1'-107') -IGLC2*01 (108'-213')]; dimer (220-220'':221-221'':224-224'':227-227'')-tetrakisdisulfide

vantictumab — immunoglobuline G2-lambda, anti-[*Homo sapiens* récepteur de la famille frizzled (FZD), incluant FZD1, FZD2, FZD5, FZD7 et FZD8)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma2 (1-443) [*Homo sapiens* VH (IGHV3-23*04 (90.80%) -(IGHD)-IGHJ6*01 T123>L (113)) [8.8.11] (1-118) - IGHG2*01 (CH1 (119-216), charnière (217-228), CH2 (229-337), CH3 (338-441), CHS (442-443)) (119-443)], (132-212')-disulfure avec la chaîne légère lambda (1'-213') [*Homo sapiens* V-LAMBDA (IGLV3-25*02 (81.60%) -IGLJ2*01) [6.3.10] (1'-107') -IGLC2*01 (108'-213')]; dimère (220-220'':221-221'':224-224'':227-227'')-tétrakisdisulfure

vantictumab — inmunoglobulina G2-lambda, anti-[receptor de la familia frizzled (FZD) de *Homo sapiens*, incluyendo FZD1, FZD2, FZD5, FZD7 et FZD8)], anticuerpo monoclonal de *Homo sapiens* ;
cadena pesada gamma2 (1-443) [*Homo sapiens* VH (IGHV3-23*04 (90.80%) -(IGHD)-IGHJ6*01 T123>L (113)) [8.8.11] (1-118) - IGHG2*01 (CH1 (119-216), bisagra (217-228), CH2 (229-337), CH3 (338-441), CHS (442-443)) (119-443)], (132-212')-disulfuro con la cadena ligera lambda (1'-213') [*Homo sapiens* V-LAMBDA (IGLV3-25*02 (81.60%) -IGLJ2*01) [6.3.10] (1'-107') -IGLC2*01 (108'-213')]; dímero (220-220'':221-221'':224-224'':227-227'')-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS HYTLSWVRQA PGKGLEWVSV  50
ISGDGSYTYY ADSVKGRFTI SSDNSKNTLY LQMNSLRAED TAVYYCARNF 100
IKYVFANWGQ GTLVTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSNFGTQTYT 200
CNVDHKPSNT KVDKTVERKC CVECPPCPAP PVAGPSVFLF PPKPKDTLMI 250
SRTPEVTCVV VDVSHEDPEV QFNWYVDGVE VHNAKTKPRE EQFNSTFRVV 300
SVLTVVHQDW LNGKEYKCKV SNKGLPAPIE KTISKTKGQP REPQVYTLPP 350
SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPMLDSDGS 400
FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL SPG        443
```

Light chain / Chaîne légère / Cadena ligera

```
DIELTQPPSV SVAPGQTARI SCSGDNIGSF YVHWYQQKPG QAPVLVIYDK  50
SNRPSGIPER FSGSNSGNTA TLTISGTQAE DEADYYCQSY ANTLSLVFGG 100
GTKLTVLGQP KAAPSVTLFP PSSEELQANK ATLVCLISDF YPGAVTVAWK 150
ADSSPVKAGV ETTTPSKQSN NKYAASSYLS LTPEQWKSHR SYSCQVTHEG 200
STVEKTVAPT ECS                                         213
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 145-201 258-318 364-422
22"-96" 145"-201" 258"-318" 364"-422"
Intra-L (C23-C104) 22'-87' 135'-194'
22'"-87'" 135'"-194'"
Inter-H-L (CH1 10-CL 126) 132-212' 132"-212'"
Inter-H-H (h 4, h 5, h 8, h 11) 220-220" 221-221" 224-224" 227-227"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
294, 294"

vatiquinonum

vatiquinone — 2-[(3*R*,6*E*,10*E*)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trien-1-yl]-3,5,6-trimethylcyclohex-2,5-diene-1,4-dione

vatiquinone — 2-[(3*R*,6*E*,10*E*)-3-hydroxy-3,7,11,15-tétraméthylhexadéca-6,10,14-trién-1-yl]-3,5,6-triméthylcyclohexa-2,5-diène-1,4-dione

vatiquinona — 2-[(3*R*,6*E*,10*E*]-3-hidroxi-3,7,11,15-tetrametilhexadeca-6,10,14-trien-1-il]-3,5,6-trimetilciclohexa-2,5-dieno-1,4-diona

$C_{29}H_{44}O_3$



vedroprevirum

vedroprevir — 1-{[(2*S*,4*R*)-1-{(2*S*)-2-[({[(1*R*,3*r*,5*S*)-bicyclo[3.1.0]hexan-3-yl]oxy}carbonyl)amino]-3,3-dimethylbutanoyl}-4-((8-chloro-7-[2-(morpholin-4-yl)ethoxy]-2-{2-[(propan-2-yl)amino]-1,3-thiazol-4-yl}quinolin-4-yl)oxy]pyrrolidin-2-yl]carbonylamino}-2-ethylcyclopropane-1-carboxylic acid

védroprévir — acide 1-{[(2*S*,4*R*)-1-{(2*S*)-2-[({[(1*R*,3*r*,5*S*)-bicyclo[3.1.0]hexan-3-yl]oxy}carbonyl)amino]-3,3-diméthylbutanoyl}-4-((8-chloro-7-[2-(morpholin-4-yl)éthoxy]-2-{2-[(propan-2-yl)amino]-1,3-thiazol-4-yl}quinoléin-4-yl)oxy]pyrrolidin-2-yl]carbonylamino}-2-éthylcyclopropane-1-carboxylique

vedroprevir — ácido 1-{[(2*S*,4*R*)-1-{(2*S*)-2-[({[(1*R*,3*r*,5*S*)-biciclo[3.1.0]hexan-3-il]oxi}carbonil)amino]-3,3-dimetilbutanoil}-4-((8-cloro-7-[2-(morfolin-4-il)etoxi]-2-{2-[(propan-2-il)amino]-1,3-tiazol-4-il}quinolin-4-il)oxi]pirrolidin-2-il]carbonilamino}-2-etilciclopropano-1-carboxílico

$C_{45}H_{60}ClN_7O_9S$



vericiguatum

vericiguat — methyl [4,6-diamino-2-{5-fluoro-1-[(2-fluorophenyl)methyl]-1*H*-pyrazolo[3,4-*b*]pyridin-3-yl}pyrimidin-5-yl]carbamate

véricigu at — [4,6-diamino-2-{5-fluoro-1-[(2-fluorophényl)méthyl]-1*H*-pyrazolo[3,4-*b*]pyridin-3-yl}pyrimidin-5-yl]carbamate de méthyle

vericiguat — *N*-{4,6-diamino-2-[5-fluoro-1-[(2-fluorofenil)metil]-1*H*-pirazolo[3,4-*b*]-piridin-3-il]pirimidin-5-il}carbamato de metilo

$C_{19}H_{16}F_2N_8O_2$



vilaprisanum

vilaprisan — 20,20,21,21,21-pentafluoro-17-hydroxy-11β-[4-(methanesulfonyl)phenyl]-19-nor-17α-pregna-4,9-dien-3-one

vilaprisan — 20,20,21,21,21-pentafluoro-17-hydroxy-11β-[4-(méthanesulfonyl)phényl]-19-nor-17α-prégna-4,9-dién-3-one

vilaprisán — 20,20,21,21,21-pentafluoro-17-hidroxi-11β-[4-(metanosulfonil)fenil]-19-nor-17α-pregna-4,9-dien-3-ona

$C_{27}H_{29}F_5O_4S$



voruciclibum

voruciclib	2-[2-chloro-4-(trifluoromethyl)phenyl]-5,7-dihydroxy-8-[(2*R*,3*S*)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]-4*H*-1-benzopyran-4-one
voruciclib	2-[2-chloro-4-(trifluoromethyl)phenyl]-5,7-dihydroxy-8-[(2*R*,3*S*)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]-4*H*-1-benzopyran-4-one
voruciclib	2-[2-cloro-4-(trifluorometil)fenil]-5,7-dihidroxi-8-[(2*R*,3*S*)-2-(hidroximetil)-1-metilpirrolidin-3-il]-4*H*-1-benzopiran-4-ona

$C_{22}H_{19}ClF_3NO_5$



Electronic structure available on Mednet: http://mednet.who.int/
Structure électronique disponible sur Mednet: http://mednet.who.int/
Estructura electrónica disponible en Mednet: http://mednet.who.int/

* http://www.who.int/entity/medicines/services/inn/Radical_Book_2012.pdf

AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES

Recommended International Nonproprietary Names (Rec. INN): List 1
(Chron. Wld Hlth Org., Vol. 9, No 6, 1955)

p. 190	*delete*	*insert*
	methacholinii chloridum	**methacholini chloridum**
	methacholinium chloride	methacholine chloride

Dénominations communes internationales recommandées (DCI rec.): Liste 1
(Chron. Org. mond. Santé, Vol. 9, No 6, 1955)

p. 206	*supprimer*	*insérer*
	methacholinii chloridum	**methacholini chloridum**
	chlorure de méthacholinium	chlorure de méthacholine

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 1
(Crón. Org. mund. Salud, Vol. 9, No 6, 1955)

p. 209	*suprimáse*	*insertese*
	methacholinii chloridum	**methacholini chloridum**
	cloruro de metacolinio	cloruro de metacolina

Recommended International Nonproprietary Names (Rec. INN): List 3
(Chron. Wld Hlth Org., Vol. 13, No. 12, 1959)

p. 463	*delete*	*insert*
	acetylcholinii chloridum	**acetylcholini chloridum**
p. 465	*delete*	*insert*
	cholinii chloridum	**cholini chloridum**
p. 470	*delete*	*insert*
	nitricholinii perchloras	**nitricholini perchloras**
	nitricholinium perchlorate	nitricholine perchlorate

Dénominations communes internationales recommandées (DCI rec.): Liste 3
(Chron. Org. mond. Santé, Vol. 13, No. 12, 1959)

p. 482	*supprimer*	*insérer*
	acetylcholinii chloridum	**acetylcholini chloridum**

p. 484	*supprimer*	*insérer*
	cholinii chloridum	**cholini chloridum**
p. 489	*supprimer*	*insérer*
	nitricholinii perchloras	**nitricholini perchloras**
	perchlorate de nitricholinium	perchlorate de nitricholine

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 3
(Crón. Org. mund. Salud, Vol. 13, No. 12, 1959)

p. 496	*suprimáse*	*insertese*
	acetylcholinii chloridum	**acetylcholini chloridum**
p. 498	*suprimáse*	*insertese*
	cholinii chloridum	**cholini chloridum**
p. 503	*suprimáse*	*insertese*
	nitricholinii perchloras	**nitricholini perchloras**
	perclorato de nitricolinio	perclorato de nitrocolina

Recommended International Nonproprietary Names (Rec. INN): List 4
(Chron. Wld Hlth Org., Vol. 16, No. 3, 1962)

p. 103	*delete*	*insert*
	cholinii gluconas	**cholini gluconas**
	cholinium gluconate	choline gluconate

Dénominations communes internationales recommandées (DCI rec.): Liste 4
(Chron. Org. mond. Santé, Vol. 16, No. 3, 1962)

p. 114	*supprimer*	*insérer*
	cholinii gluconas	**cholini gluconas**
	gluconate de cholinium	gluconate de choline

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 4
(Crón. Org. mund. Salud, Vol. 16, No. 3, 1962)

p. 154	*suprimáse*	*insertese*
	cholinii gluconas	**cholini gluconas**
	gluconato de colinio	gluconato de colina

Recommended International Nonproprietary Names (Rec. INN): List 62
Dénominations communes internationales recommandées (DCI Rec.): Liste 62
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 62
(WHO Drug Information, Vol. 23, No. 3, 2009)

p. 258 & 259 **ramucirumabum #**

ramucirumab — *replace the description and the structure by the following ones*
ramucirumab — *remplacer la description et la structure par les suivantes*
ramucirumab — *sustitúyase la descripción y la estructura por los siguientes*

immunoglobulin G1-kappa, anti-[*Homo sapiens* KDR (kinase insert domain receptor, vascular endothelial growth factor receptor 2, VEGFR2, VEGF-R2, FLK1, CD309) extracellular domain], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-446) [*Homo sapiens* VH (IGHV3-21*01(99.00%) -(IGHD)-IGHJ3*02) [8.8.9] (1-116) - IGHG1*03 (CH1 F5>L (125), hinge (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-12*01 (85.30%) -IGKJ4*01 E125>D (105)) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer (225-225'':228-228'')-bisdisulfide

immunoglobuline G1-kappa, anti-[*Homo sapiens* KDR (récepteur à domaine insert kinase, récepteur 2 du facteur de croissance endothélial vasculaire, VEGFR2, VEGF-R2, FLK1, CD309) domaine extracellulaire], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-446) [*Homo sapiens* VH (IGHV3-21*01 (99.00%) -(IGHD)-IGHJ3*02) [8.8.9] (1-116) -IGHG1*03 (CH1 F5>L (125), charnière (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-12*01 (85.30%) -IGKJ4*01 E125>D (105)) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (225-225'':228-228'')-bisdisulfure

inmunoglobulina G1-kappa, anti-[*Homo sapiens* KDR (receptor con dominio insert-kinasa, receptor 2 del factor de crecimiento endotelial vascular, VEGFR2, VEGF-R2, FLK1, CD309) dominio extracelular], *Homo sapiens* anticuerpo monoclonal;
cadena pesada gamma1 (1-446) [*Homo sapiens* VH (IGHV3-21*01 (99.00%) -(IGHD)-IGHJ3*02) [8.8.9] (1-116) -IGHG1*03 (CH1 F5>L (125), bisagra (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-12*01 (85.30%) -IGKJ4*01 E125>D (105)) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (225-225'':228-228'')-bisdisulfuro
Error! Objects cannot be created from editing field codes.

Recommended International Nonproprietary Names (Rec. INN): List 67
Dénominations communes internationales recommandées (DCI Rec.): Liste 67
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 67
(WHO Drug Information, Vol. 26, No. 1, 2012)

p. 91 **upamostatum**

upamostat — *replace the chemical name by the following one*
upamostat — *remplacer le nom chimique par le suivant*
upamostat — *sustitúyase el nombre químico por el siguiente*
ethyl 4-{(2*S*)-3-{3-[(*E*)-*N*'-hydroxycarbamimidoyl]phenyl}-2-[2,4,6-tri(propan-2-yl)benzenesulfonamido]propanoyl}piperazine-1-carboxylate}

4-{(2*S*)-3-{3-[(*E*)-*N*'-hydroxycarbamimidoyl]phényl}-2-[2,4,6-tri(propan-2-yl)benzènesulfonamido]propanoyl}pipérazine-1-carboxylate d'éthyle

4-{(2*S*)-3-{3-[(*E*)-*N*'-hidroxicarbamimidoil]fenil}-2-[2,4,6-tri(propan-2-il)bencenosulfonamido]propanoil}piperazina-1-carboxilato de etilo

Recommended International Nonproprietary Names (Rec. INN): List 69

Dénominations communes internationales recommandées (DCI Rec.): Liste 69
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 69
(WHO Drug Information, Vol. 27, No. 1, 2013)

p. 82 **tenapanorum**

tenapanor — *replace the chemical name by the following one*
téna panor — *remplacer le nom chimique par le suivant*
tenapanor — *sustitúyase el nombre químico por el siguiente*

N,*N*'-(10,17-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosane-1,26-diyl)bis{3-[(4*S*)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl]benzenesulfonamide}

N,*N*'-(10,17-dioxo-3,6,21,24-tétraoxa-9,11,16,18-tétraazahexacosane-1,26-diyl)bis{3-[(4*S*)-6,8-dichloro-2-méthyl-1,2,3,4-tétrahydroisoquinoléin-4-yl]benzènesulfonamide}

N,*N*'-(10,17-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosano-1,26-diyl)bis{3-[(4*S*)-6,8-dicloro-2-metil-1,2,3,4-tetrahidroisoquinolin-4-il]bencenosulfonamida}

Recommended International Nonproprietary Names (Rec. INN): List 70
Dénominations communes internationales recommandées (DCI Rec.): Liste 70
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 70
(WHO Drug Information, Vol. 27, No. 3, 2013)

p. 306 **polatuzumabum vedotinum #**
& 307

polatuzumab vedotin — *replace the description by the following one*
polatuzumab védotine — *remplacer la description par la suivante*
polatuzumab vedotina — *sustitúyase la descripción por la siguiente*

immunoglobulin G1-kappa auristatin E conjugate, anti-[*Homo sapiens* CD79B (immunoglobulin-associated CD79 beta)], humanized monoclonal antibody conjugated to auristatin E;
gamma1 heavy chain (1-447) [humanized VH (*Homo sapiens* IGHV3-23*04 (76.50%) -(IGHD)-IGHJ4*01) [8.8.10] (1-117) -*Homo sapiens* IGHG1*03 (CH1 R120>K (214) (118-215), hinge (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (85.90%) -IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')]; dimer (226-226":229-229")-bisdisulfide; conjugated, on an average of 3 to 4 cysteinyl, to monomethylauristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinyl-*p*-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker
For the *vedotin* part, please refer to the document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

immunoglobuline G1-kappa conjuguée à l'auristatine E, anti-[*Homo sapiens* CD79B (CD79 bêta associé à l'immunoglobuline)], anticorps monoclonal humanisé conjugué à l'auristatine E;
chaîne lourde gamma1 (1-447) [VH humanisé (*Homo sapiens* IGHV3-23*04 (76.50%) -(IGHD)-IGHJ4*01) [8.8.10] (1-117) -*Homo sapiens* IGHG1*03 (CH1 R120>K (214) (118-215), charnière (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-218')-disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (85.90%) -IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')]; dimère (226-226":229-229")-bisdisulfure; conjugué, sur 3 à 4 cystéinyl en moyenne, au monométhylauristatine E (MMAE), via un linker clivable de type maléimidocaproyl-valyl-citrullinyl-*p*-aminobenzyloxycarbonyl (mc-val-cit-PABC)
Pour la partie *védotine*, veuillez vous référer au document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

inmunoglobulina G1-kappa conjugada con auristatina E, anti-[*Homo sapiens* CD79B (CD79 beta associado a la inmunoglobulina)], anticuerpo monoclonal humanizado conjugado con auristatina E;
cadena pesada gamma1 (1-447) [VH humanizado (*Homo sapiens* IGHV3-23*04 (76.50%) -(IGHD)-IGHJ4*01) [8.8.10] (1-117) -*Homo sapiens* IGHG1*03 (CH1 R120>K (214) (118-215), bisagra (216-230), CH2 (231-340), CH3 (341-445), CHS

(446-447)) (118-447)], (220-218')-disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (85.90%) -IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')]; dímero (226-226":229-229")-bisdisulfuro; conjuguado, en 3 a 4 restos cisteinil por término medio, con monometilauristatina E (MMAE), mediante un vínculo escindible maleimidocaproil-valil-citrullinil-*p*-aminobenziloxicarbonil (mc-val-cit-PABC)
Para la fracción *vedotina* se pueden referir al documento *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

p. 313 **sofosbuvirum**

sofosbuvir	*replace the structure by the following one*
sofosbuvir	*remplacer la structure par la suivante*
sofosbuvir	*sustitúyase la estructura por la siguiente*



Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.